



Mark Genovese

James W. Raitt M.D. Professor, Emeritus
Medicine - Immunology & Rheumatology

CLINICAL OFFICES

- **Immunology and Rheumatology Clinic**

900 Blake Wilbur Dr Rm W2081

2nd Fl

Stanford, CA 94305

Tel (650) 723-6961 **Fax** (650) 723-3059

Bio

BIO

Mark C. Genovese, MD, is the James W. Raitt Professor of Medicine and Director of the Rheumatology Clinic in the Division of Immunology and Rheumatology at Stanford University Medical Center. He received his bachelor's degree from the University of Notre Dame and his medical degree from the Johns Hopkins University School of Medicine. He completed an internship, residency, and chief residency in the Department of Medicine at Stanford University. He remained at Stanford as a fellow in the Division of Immunology and Rheumatology and subsequently joined the faculty in the same division and serving as the clinic chief. Dr. Genovese has established a clinical research program that is focused on bench-to-bedside translational medicine in autoimmune diseases. He has designed and led numerous investigator-initiated studies and international multi-center trials investigating novel therapies and therapeutic strategies for the treatment of autoimmune disease and arthritis. In addition, he actively collaborates with other investigators on studies of biomarkers, chemokines, cytokines, and cell surface markers associated with disease progression and response to therapy in various autoimmune diseases and arthritis.

CLINICAL FOCUS

- Rheumatology
- Immunology/Rheumatology

ACADEMIC APPOINTMENTS

- Professor Emeritus-Hourly, Medicine - Immunology & Rheumatology

PROFESSIONAL EDUCATION

- Fellowship: Stanford University Immunology and Rheumatology Fellowship (1998) CA
- Residency: Stanford University Internal Medicine Residency (1996) CA
- Residency: Stanford University Internal Medicine Residency (1995) CA
- Internship: Stanford University Internal Medicine Residency (1993) CA
- Medical Education: Johns Hopkins University School of Medicine (1992) MD
- Board Certification: Rheumatology, American Board of Internal Medicine (1998)

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

Clinical trials and interventions in the rheumatic diseases including Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis, Osteoarthritis.

CLINICAL TRIALS

- Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis, Recruiting
- A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis, Not Recruiting
- A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis, Not Recruiting
- A Pilot Trial of Adalimumab for the Treatment of Osteoarthritis, Not Recruiting
- Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease, Not Recruiting
- Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Have Active Disease, Not Recruiting
- Hydroxychloroquine/Atorvastatin in the Treatment of Osteoarthritis (OA) of the Knee, Not Recruiting
- Switching Anti-TNF-Alpha Agents in Rheumatoid Arthritis (RA), Not Recruiting

Publications

PUBLICATIONS

- **Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis.** *Arthritis research & therapy*
Combe, B., Rahman, P., Kameda, H., Canete, J. D., Gallo, G., Agada, N., Xu, W., Genovese, M. C.
2020; 22 (1): 14
- **Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis.** *RMD open*
Smolen, J. S., Choe, J. Y., Weinblatt, M. E., Emery, P., Keystone, E., Genovese, M. C., Myung, G., Hong, E., Baek, I., Ghil, J.
2020; 6 (1)
- **FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension.** *Arthritis research & therapy*
Genovese, M. C., Glover, J., Greenwald, M., Porawska, W., El Khouri, E. C., Dokoupilova, E., Vargas, J. I., Stanislavchuk, M., Kellner, H., Baranova, E., Matsunaga, N., Alten, R.
2019; 21 (1): 281
- **Unique Sjogren's syndrome patient subsets defined by molecular features.** *Rheumatology (Oxford, England)*
James, J. A., Guthridge, J. M., Chen, H., Lu, R., Bourn, R. L., Bean, K., Munroe, M. E., Smith, M., Chakravarty, E., Baer, A. N., Noaiseh, G., Parke, A., Boyle, et al
2019
- **Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study.** *Rheumatology and therapy*
Genovese, M. C., Greenwald, M. W., Gutierrez-Urena, S. R., Cardiel, M. H., Pooley, J. E., Zubrzycka-Sienkiewicz, A., Coddling, C. E., Wang, A., He, W., Amos, R., Vinuesa, R., Wang, X., Garg, et al
2019
- **Patient Perceptions of Unmet Medical Need in Rheumatoid Arthritis: A Cross-Sectional Survey in the USA.** *Rheumatology and therapy*
Radawski, C., Genovese, M. C., Hauber, B., Nowell, W. B., Hollis, K., Gaich, C. L., DeLozier, A. M., Gavigan, K., Reynolds, M., Cardoso, A., Curtis, J. R.
2019
- **MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis** *JOURNAL OF RHEUMATOLOGY*
Peterfy, C., DiCarlo, J., Emery, P., Genovese, M. C., Keystone, E. C., Taylor, P. C., Schlichting, D. E., Beattie, S. D., Luchi, M., Macias, W.
2019; 46 (8): 887–95

- **Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.** *JAMA*
Genovese, M. C., Kalunian, K., Gottenberg, J., Mozaffarian, N., Bartok, B., Matzkies, F., Gao, J., Guo, Y., Tasset, C., Sundry, J. S., de Vlam, K., Walker, D., Takeuchi, et al
2019; 322 (4): 315–25
- **Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up.** *Rheumatology (Oxford, England)*
Fleischmann, R., Genovese, M. C., Lin, Y., St John, G., van der Heijde, D., Wang, S., Gomez-Reino, J. J., Maldonado-Cocco, J. A., Stanislav, M., Kivitz, A. J., Burmester, G. R.
2019
- **Upadacitinib versus Placebo or Adalimumab in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase 3, Double-Blind, Randomized Controlled Trial.** *Arthritis & rheumatology (Hoboken, N.J.)*
Fleischmann, R., Pangan, A. L., Song, I., Mysler, E., Bessette, L., Peterfy, C., Durez, P., Ostor, A. J., Li, Y., Zhou, Y., Othman, A. A., Genovese, M. C.
2019
- **Long-Term Safety of Ixekizumab in 17034.7 Patient-Years from 15 Global Clinical Trials in Psoriasis and Psoriatic Arthritis: 3-Year Results**
Combe, B., Rahman, P., Kameda, H., Canete, J., Gallo, G., Agada, N., Xu, W., Genovese, M., Janos, B.
J RHEUMATOL PUBL CO.2019: 845
- **Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 6 Years: An Updated Integrated Safety Analysis**
Keystone, E., Genovese, M., Smolen, J., Takeuchi, T., Rooney, T., Dickson, C., Saifan, C., Cardoso, A., Issa, M., Ishii, T., Winthrop, K.
J RHEUMATOL PUBL CO.2019: 804–5
- **Assessment of Pain Relief with Baricitinib in Patients with Refractory Rheumatoid Arthritis**
Pope, J., Quebe, A., Zhu, B., Sun, L., Gaich, C., De Leonardis, F., Cardoso, A., Genovese, M.
J RHEUMATOL PUBL CO.2019: 807
- **Dose Reduction of Baricitinib in Patients with Rheumatoid Arthritis Achieving Sustained Disease Control: Results of a Prospective Study**
Takeuchi, T., Genovese, M., Haraoui, B., Li, Z., Xie, L., Klar, R., Correia, A., Otawa, S., Lopez-Romero, P., de la Torre, I., Rooney, T., Smolen, J.
J RHEUMATOL PUBL CO.2019: 807–8
- **CLINICAL SIMILARITY OF ABP 710 WITH INFLIXIMAB (REFERENCE PRODUCT) IN SUBJECTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS**
Genovese, M. C., Sanchez-Burson, J., Oh, M., Balazs, E., Neal, J., Fanjiang, G., Cohen, S.
BMJ PUBLISHING GROUP.2019: 1648–49
- **SAFETY AND EFFECTIVENESS OF UPADACITINIB OR ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS AT 48 WEEKS FROM THE SELECT-COMPARE STUDY**
Fleischmann, R., Enejosa, J., Song, I., Mysler, E., Bessette, L., Peterfy, C., Durez, P., Ostor, A., Li Yihan, Zhou, Y., Genovese, M. C.
BMJ PUBLISHING GROUP.2019: 744–45
- **SWITCHING BETWEEN THE JAK1-SELECTIVE INHIBITOR-UPADACITINIB AND ADALIMUMAB FOLLOWING INITIAL NON-RESPONSE: CLINICAL AND FUNCTIONAL OUTCOMES AMONG RHEUMATOID ARTHRITIS PATIENTS**
Genovese, M. C., Fleischmann, R., Blanco, R., Hall, S., Thomson, G., van den Bosch, F., Zerbini, C., Enejosa, J., Li Yihan, Demasi, R., Song, I.
BMJ PUBLISHING GROUP.2019: 83–84
- **SYSTEMATIC ANALYSIS OF INJECTION-SITE PAIN CAUSED BY SUBCUTANEOUS ADMINISTRATION OF THE ADALIMUMAB BIOSIMILAR FKB327 VERSUS ADMINISTRATION OF THE ADALIMUMAB REFERENCE PRODUCT VIA DIFFERENT DELIVERY METHODS**
Alten, R., Genovese, M. C., Boyce, M., Yonemura, T., Ito, T., Kellner, H.
BMJ PUBLISHING GROUP.2019: 699
- **LONG-TERM SAFETY, IMMUNOGENICITY AND EFFICACY IN RANDOMIZED, DOUBLE-BLIND, AND OPEN-LABEL EXTENSION STUDIES COMPARING FKB327, AN ADALIMUMAB BIOSIMILAR, WITH THE ADALIMUMAB REFERENCE PRODUCT IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS**
Alten, R., Genovese, M. C., Arai, Muniz, R., Kellner, H.
BMJ PUBLISHING GROUP.2019: 1135
- **SAFETY AND EFFICACY OF LY3337641, A BRUTON'S TYROSINE KINASE INHIBITOR IN PATIENTS WITH RHEUMATOID ARTHRITIS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-PART PHASE 2 STUDY**
Genovese, M. C., Spindler, A., Sagawa, A., Park, W., Dudek, A., Kivitz, A., Chao, J., Chan, L., Barchuk, W., Nirula, A.

BMJ PUBLISHING GROUP.2019: 1109–10

- **EFFECT OF SARILUMAB ON GLYCOSYLATED HEMOGLOBIN IN PATIENTS WITH RHEUMATOID ARTHRITIS AND DIABETES**
Genovese, M. C., Burmester, G., Hagino, O., van Hoogstraten, H., Mangan, E., Thangavelu, K., Fleischmann, R., Mandrup-Poulsen, T.
BMJ PUBLISHING GROUP.2019: 1128–29
- **INHIBITION OF STRUCTURAL JOINT DAMAGE WITH UPADACITINIB AS MONOTHERAPY OR IN COMBINATION WITH METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS: 1 YEAR OUTCOMES FROM THE SELECT PHASE 3 PROGRAM**
Peterfy, C., Genovese, M. C., Song, I., Friedman, A., Hall, S., Mysler, E., Durez, P., Baraliakos, X., Enejosa, J., Shaw, T., Li Yihan, Su Chen, Strand, V.
BMJ PUBLISHING GROUP.2019: 369–70
- **FILGOTINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGICAL DMARDS (BDMARD-IR) BY RACE & GEOGRAPHIC REGION**
Gottenberg, J., Genovese, M. C., Kalunian, K., Mozaffarian, N., Bartok, B., Matzkies, F., Gao, J., Guo, Y., Walker, D., Takeuchi, T., de Vlam, K.
BMJ PUBLISHING GROUP.2019: 361
- **SHORT DURATION OF CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (CSDMARDS) BEFORE AND AFTER BECOMING A CSDMARD INADEQUATE RESPONDER IN RHEUMATOID ARTHRITIS PATIENTS**
Dore, R. K., Antonova, J., Huan, H., Gorritz, M., Genovese, M. C.
BMJ PUBLISHING GROUP.2019: 700
- **PATIENTS (PTS) SWITCHED TO SARILUMAB FROM ADALIMUMAB ACHIEVE CLINICALLY IMPORTANT IMPROVEMENTS IN RA DISEASE ACTIVITY: RESULTS FROM MONARCH TRIAL OPEN-LABEL EXTENSION (OLE)**
Burmester, G., Amital, H., Rubbert-Roth, A., van Hoogstraten, H., Gervitz, L., Thangavelu, K., St John, G., Genovese, M. C.
BMJ PUBLISHING GROUP.2019: 1138–39
- **TREATMENT PATTERNS, PERSISTENCE, AND DURABILITY IN RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (BDMARDS)**
Dore, R. K., Antonova, J., Burudpakdee, C., Wang, X., Ozbay, B., Genovese, M. C.
BMJ PUBLISHING GROUP.2019: 1135–36
- **SAFETY PROFILE OF BARICITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS UP TO 7 YEARS: AN UPDATED INTEGRATED SAFETY ANALYSIS**
Genovese, M. C., Smolen, J. S., Takeuchi, T., Burmester, G., Brinker, D., Rooney, T., Zhong, J., Mo, D., Saifan, C., Cardoso, A., Issa, M., Wu, W., Winthrop, et al
BMJ PUBLISHING GROUP.2019: 308–9
- **HIGH UNMET NEED AMONG RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO BIOLOGIC DMARD: REAL-WORLD ANALYSIS OF 2012-2016 US MEDICARE DATA**
Dore, R. K., Antonova, J., Guo, H., Li Suying, Ozbay, B., Genovese, M. C.
BMJ PUBLISHING GROUP.2019: 1640
- **SAFETY AND EFFICACY OF FILGOTINIB IN ACTIVE RHEUMATOID ARTHRITIS BY PRIOR BIOLOGICAL DMARD EXPOSURE IN PATIENTS WITH PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGICAL DMARDS (BDMARD-IR)**
Genovese, M. C., Kalunian, K., Gottenberg, J., Mozaffarian, N., Bartok, B., Matzkies, F., Gao, J., Guo, Y., de Vlam, K., Walker, D., Takeuchi, T.
BMJ PUBLISHING GROUP.2019: 709–10
- **FIRST-IN-HUMAN STUDY OF NOVEL IMPLANTED VAGUS NERVE STIMULATION DEVICE TO TREAT RHEUMATOID ARTHRITIS**
Genovese, M. C., Gaylis, N., Sikes, D., Kivitz, A., Horowitz, D. M., Peterfy, C., Levine, Y., Chernoff, D.
BMJ PUBLISHING GROUP.2019: 264
- **GS-9876, A NOVEL, HIGHLY SELECTIVE, SYK INHIBITOR IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: SAFETY, TOLERABILITY AND EFFICACY RESULTS OF A PHASE 2 STUDY**
Kivitz, A., Mehta, D., Matzkies, F., Mozaffarian, A., Kunder, R., Di Paolo, J. A., Mozaffarian, N., Hsueh, S., Kim, J., Jiang, W., Liu, L., Sundry, J., Genovese, et al
BMJ PUBLISHING GROUP.2019: 746–47
- **SAFETY AND EFFICACY OF FILGOTINIB IN PATIENTS AGED 65 YEARS AND OLDER: RESULTS FROM A PHASE 3 STUDY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGICAL DMARDS (BDMARD-IR)**
Kalunian, K., Gottenberg, J., Genovese, M. C., Mozaffarian, N., Bartok, B., Matzkies, F., Gao, J., Guo, Y., Takeuchi, T., de Vlam, K., Walker, D.
BMJ PUBLISHING GROUP.2019: 748–49

- **SAFETY AND EFFICACY OF FILGOTINIB IN JAPANESE PATIENTS ENROLLED IN A GLOBAL PHASE 3 TRIAL OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGIC DMARDS**
Takeuchi, T., Matsubara, T., Atsumi, T., Amano, K., Ishiguro, N., Sugiyama, E., Yamaoka, K., Genovese, M. C., Kalunian, K., Walker, D., Gottenberg, J., de Vlam, K., Mozaffarian, et al
BMJ PUBLISHING GROUP.2019: 1686–87
- **UPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGICAL DMARDS: RESULTS AT 60 WEEKS FROM THE SELECT-BEYOND STUDY**
Genovese, M. C., Combe, B., Hall, S., Rubbert-Roth, A., Zhong, S., Meerwein, S., Pangan, A., Fleischmann, R.
BMJ PUBLISHING GROUP.2019: 360–61
- **FENEBRUTINIB COMPARED TO PLACEBO AND ADALIMUMAB IN PATIENTS WITH INADEQUATE RESPONSE TO EITHER METHOTREXATE THERAPY OR PRIOR TNF THERAPY: PHASE 2 STUDY**
Cohen, S., Tuckwell, K., Katsumoto, T. R., Zhao, R., Lee, C., Berman, A., Damjanov, N., Fedkov, D., Jeka, S., Genovese, M. C.
BMJ PUBLISHING GROUP.2019: 80–81
- **ASSESSMENT OF PAIN IMPROVEMENT IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH BARICITINIB, WHO WERE INADEQUATE RESPONDERS TO METHOTREXATE AND TUMOR NECROSIS FACTOR INHIBITORS**
Taylor, P. C., Fleischmann, R., Takeuchi, T., Pope, J., Genovese, M. C., Zhu, B., Gaich, C., Zhang, X., Dickson, C., Quebe, A., De Leonadis, F., Cardoso, A., Kouris, et al
OXFORD UNIV PRESS.2019: 72
- **SAFETY AND EFFICACY OF FILGOTINIB IN A PHASE 3 TRIAL OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS**
Walker, D., Genovese, M. C., Kalunian, K., Gottenberg, J., de Vlam, K., Mozaffarian, N., Bartok, B., Matzkies, F., Gao, J., Guo, Y., Tasset, C., Sundry, J. S., Takeuchi, et al
OXFORD UNIV PRESS.2019
- **Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study**
Takeuchi, T., Genovese, M. C., Haraoui, B., Li, Z., Xie, L., Klar, R., Pinto-Correia, A., Ottawa, S., Lopez-Romero, P., de la Torre, I., Macias, W., Rooney, T. P., Smolen, et al
BMJ PUBLISHING GROUP.2019: 171–78
- **Use of Magnetic Resonance Imaging to Support Dose Selection in a Phase II Trial of Baricitinib Combined with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis.** *The Journal of rheumatology*
Peterfy, C., DiCarlo, J., Emery, P., Genovese, M. C., Keystone, E. C., Taylor, P. C., Schlichting, D. E., Beattie, S. D., Luchi, M., Macias, W.
2019
- **Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment** *JOURNAL OF RHEUMATOLOGY*
Smolen, J. S., Genovese, M. C., Takeuchi, T., Hyslop, D. L., Macias, W. L., Rooney, T., Chen, L., Dickson, C. L., Camp, J., Cardillo, T. E., Ishii, T., Winthrop, K. L.
2019; 46 (1): 7–18
- **Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment.** *RMD open*
Genovese, M. C., van der Heijde, D., Lin, Y., St John, G., Wang, S., van Hoogstraten, H., Gomez-Reino, J. J., Kivitz, A., Maldonado-Cocco, J. A., Seriola, B., Stanislav, M., Burmester, G. R.
2019; 5 (2): e000887
- **TNF-alpha inhibition for the treatment of cardiac sarcoidosis.** *Seminars in arthritis and rheumatism*
Baker, M. C., Sheth, K., Witteles, R., Genovese, M. C., Shoor, S., Simard, J. F.
2019
- **Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension.** *RMD open*
Burmester, G. R., Strand, V., Rubbert-Roth, A., Amital, H., Raskina, T., Gomez-Centeno, A., Pena-Rossi, C., Gervitz, L., Thangavelu, K., St John, G., Boklage, S., Genovese, M. C.
2019; 5 (2): e001017
- **Tissue metabolite of type I collagen, CIM, and CRP predicts structural progression of rheumatoid arthritis.** *BMC rheumatology*
Bay-Jensen, A. C., Platt, A., Jenkins, M. A., Weinblatt, M. E., Byrjalsen, I., Musa, K., Genovese, M. C., Karsdal, M. A.

2019; 3: 3

- **Methotrexate in the Treatment of Idiopathic Granulomatous Mastitis.** *The Journal of rheumatology*
Postolova, A., Troxell, M. L., Wapnir, I. L., Genovese, M. C.
2019
- **Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response.** *Annals of the rheumatic diseases*
Fleischmann, R. M., Genovese, M. C., Enejosa, J. V., Mysler, E., Bessette, L., Peterfy, C., Durez, P., Ostor, A., Li, Y., Song, I. H.
2019
- **Phase II Study of ABT-122, a Tumor Necrosis Factor- and Interleukin-17A-Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate** *ARTHRITIS & RHEUMATOLOGY*
Mease, P. J., Genovese, M. C., Weinblatt, M. E., Peloso, P. M., Chen, K., Othman, A. A., Li, Y., Mansikka, H. T., Khatri, A., Wishart, N., Liu, J.
2018; 70 (11): 1778–89
- **Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment.** *The Journal of rheumatology*
Smolen, J. S., Genovese, M. C., Takeuchi, T., Hyslop, D. L., Macias, W. L., Rooney, T., Chen, L., Dickson, C. L., Riddle Camp, J., Cardillo, T. E., Ishii, T., Winthrop, K. L.
2018
- **Clinical Efficacy and Safety of Baminercept, a Lymphotoxin beta Receptor Fusion Protein, in Primary Sjogren's Syndrome Results From a Phase II Randomized, Double-Blind, Placebo-Controlled Trial** *ARTHRITIS & RHEUMATOLOGY*
St Clair, E., Baer, A. N., Wei, C., Noaiseh, G., Parke, A., Coca, A., Utset, T. O., Genovese, M. C., Wallace, D. J., McNamara, J., Boyle, K., Keyes-Elstein, L., Browning, et al
2018; 70 (9): 1470–80
- **Long-Term Treatment with Sarilumab Plus Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs): Pooled Safety and Efficacy with over 4 Years' Treatment**
Genovese, M. C., van Hoogstraten, H., St John, G., Dong, Q., Jose Gomez-Reino, J., Maldonado-Cocco, J. A., Carlos Salazar, J., Huizinga, T. J., Burmester, G. R.
WILEY.2018
- **GS-9876, a Novel, Highly Selective, SYK Inhibitor in Patients with Active Rheumatoid Arthritis: Safety, Tolerability and Efficacy Results of a Phase 2 Study**
Kivitz, A. J., Mehta, D. P., Matzkies, F., Mozaffarian, A., Kunder, R., Di Paolo, J., Mozaffarian, N., Hsueh, S., Kim, J., Jiang, W., Liu, L., Sundry, J. S., Genovese, et al
WILEY.2018
- **Impact of Immunogenicity on Clinical Efficacy and Administration Related Reaction in TNF Inhibitors: A Pooled-Analysis from Three Biosimilar Studies in Patients with Rheumatoid Arthritis**
Emery, P., Weinblatt, M. E., Smolen, J. S., Keystone, E. C., Genovese, M. C., Vencovsky, J., Kay, J., Hong, E., Ghil, J.
WILEY.2018
- **Assessment of Pain Relief with Baricitinib By Treatment History in Patients with Refractory Rheumatoid Arthritis**
Pope, J. E., Quebe, A., Zhu, B., Sun, L., Gaich, C. L., de Leonardis, F., Cardoso, A., Genovese, M. C.
WILEY.2018
- **A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib to Placebo and to Adalimumab, in Patients with Active Rheumatoid Arthritis with Inadequate Response to Methotrexate**
Fleischmann, R., Pangan, A. L., Mysler, E., Bessette, L., Peterfy, C., Durez, P., Ostor, A., Li, Y., Zhou, Y., Othman, A. A., Song, I., Genovese, M. C.
WILEY.2018
- **Longitudinal Efficacy Analysis of Patients with Active Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Dmards: Response Following Rescue from Baricitinib 2mg to 4mg Once-Daily**
Fleischmann, R., Genovese, M. C., Cardoso, A., Sun, L., Chen, Y., Walls, C. D., Schlichting, D. E., Takeuchi, T., Dougados, M., Smolen, J. S., Curtis, J. R.
WILEY.2018
- **Methotrexate in the Treatment of Granulomatous Mastitis: A Retrospective Review of 19 Cases**
Postolova, A., Genovese, M. C.
WILEY.2018

- **A Phase IIa Mechanistic Study of Anti-GM-CSF (GSK3196165) with Methotrexate Treatment in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to Methotrexate**
Genovese, M. C., Berkowitz, M., Conaghan, P. G., Davy, K., Inman, D., Fischeleva, E., Gupta, A., Janiczek, R., Layton, M., Mitchell, N., Patel, J., Smith, J. E., Williamson, et al
WILEY.2018
- **Incidence of Inflammatory Bowel Disease Among Patients Treated with Ixekizumab: An Update on Adjudicated Data from an Integrated Database of Patients with Psoriasis and Psoriatic Arthritis**
Genovese, M. C., Colombel, J., Gellett, A. M., Xu, W., Hardin, D.
WILEY.2018
- **Rheumatoid Arthritis Treatment with Filgotinib: Week 132 Safety Data from a Phase 2b Open-Label Extension Study**
Kavanaugh, A., Genovese, M. C., Winthrop, K., Creenwald, M., Ponce, L., Sosa, F., Stanislavchuk, M., Mazur, M., Spindler, A., Cseuz, R., Nikulenkova, N., Glowacka-Kulesz, M., Szombati, et al
WILEY.2018
- **Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 6 Years: An Updated Integrated Safety Analysis**
Genovese, M. C., Smolen, J. S., Takeuchi, T., Rooney, T. P., Dickson, C. L., Yang, X., Saifan, C., Cardoso, A., Issa, M., Ishii, T., Winthrop, K.
WILEY.2018
- **A First-in-Man Bioelectronic Therapy for Biologic-Refractory Rheumatoid Arthritis**
Chernoff, D., Levine, Y., Peterfy, C., Genovese, M. C.
WILEY.2018
- **Unique Changes in Hemoglobin with Sarilumab Versus Adalimumab Are Independent of Better Disease Control in Patients with Rheumatoid Arthritis (RA)**
Burmestert, G. R., Hagino, O., Dong, Q., Stanislav, M., Gomez-Centeno, A., Selmi, C., Huizinga, T. J., Mangan, E., Gabay, C., Genovese, M. C.
WILEY.2018
- **Radiographic Progression Based on Baseline Demographics and Disease Characteristics from Three TNF-Alpha Inhibitor Biosimilar Studies in Patients with Rheumatoid Arthritis**
Smolen, J. S., Kang, Y., Yoo, W., Emery, P., Weinblatt, M. E., Keystone, E. C., Genovese, M. C., Myung, G., Hong, E., Baek, I., Ghil, J.
WILEY.2018
- **Patients' perceptions of unmet medical need in rheumatoid arthritis**
Curtis, J., Genovese, M., Radawski, C., Hauber, B., Nowell, W., Hollis, K., Gaich, C., DeLozier, A., Gavigan, K., Cardoso, A.
WILEY.2018: 56
- **Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2. *Rheumatology (Oxford, England)***
Genovese, M. C., Combe, B., Kremer, J. M., Tsai, T., Behrens, F., Adams, D. H., Lee, C., Kerr, L., Nash, P.
2018
- **Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis. *Rheumatology (Oxford, England)***
Genovese, M. C., Weinblatt, M. E., Mease, P. J., Aelion, J. A., Peloso, P. M., Chen, K., Li, Y., Liu, J., Othman, A. A., Khatri, A., Mansikka, H. T., Leszczynski, P.
2018
- **Dose Reduction of Baricitinib in Patients with Rheumatoid Arthritis Achieving Sustained Disease Control: Results of a Prospective Study**
Takeuchi, T., Genovese, M., Haraoui, B., Li, Z., Xie, L., Klar, R., Correia, A., Otawa, S., Lopez-Romero, P., de la Torre, I., Rooney, T., Smolen, J.
J RHEUMATOL PUBL CO.2018: 1054
- **Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 5.5 Years: An Updated Integrated Safety Analysis**
Keystone, E., Genovese, M., Smolen, J., Takeuchi, T., Hyslop, D., Macias, W., Rooney, T., Chen, L., Dickson, C., Camp, J., Cardillo, T., Ishii, T., Winthrop, et al
J RHEUMATOL PUBL CO.2018: 1003
- **Efficacy and Safety of Switching from Adalimumab to Sarilumab in an Open-label Extension of a Phase 3 Monotherapy Trial in Patients with Active Rheumatoid Arthritis**
Burmester, G., Fiore, S., Hu, C., Fay, J., Lee, E., Genovese, M.
J RHEUMATOL PUBL CO.2018: 1035

- **Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to TNF inhibitors: 52-week Results from a Phase 3 Study**
Genovese, M., Helliwell, P., Combe, B., Kremer, J., Adams, D., Lee, C., Kerr, L., Nash, P., Rahman, P.
J RHEUMATOL PUBL CO.2018: 996
- **Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.** *Lancet (London, England)*
Genovese, M. C., Fleischmann, R., Combe, B., Hall, S., Rubbert-Roth, A., Zhang, Y., Zhou, Y., Mohamed, M. F., Meerwein, S., Pangan, A. L.
2018
- **ABT-122, a Bispecific DVD-Immunoglobulin Targeting TNF- and IL-17A, in RA With Inadequate Response to Methotrexate: A Randomized, Double-Blind Study.** *Arthritis & rheumatology (Hoboken, N.J.)*
Genovese, M. C., Weinblatt, M. E., Aelion, J. A., Mansikka, H. T., Peloso, P. M., Chen, K., Li, Y., Othman, A. A., Khatri, A., Khan, N. S., Padley, R. J.
2018
- **Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes.** *Rheumatology (Oxford, England)*
Genovese, M. C., van Adelsberg, J., Fan, C., Graham, N. M., van Hoogstraten, H., Parrino, J., Mangan, E. K., Spindler, A., Huizinga, T. W., van der Heijde, D., EXTEND study investigators
2018
- **Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial.** *The Journal of rheumatology*
Genovese, M. C., Pacheco-Tena, C., Covarrubias, A., Leon, G., Mysler, E., Keiserman, M., Valente, R. M., Nash, P., Simon-Campos, J. A., Box, J., Legerton, C. W., Nasonov, E., Durez, et al
2018
- **EFFICACY AND SAFETY OF SWITCHING FROM ADALIMUMAB TO SARILUMAB IN AN OPEN-LABEL EXTENSION OF A PHASE III MONOTHERAPY TRIAL IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS**
Burmester, G. R., Fiore, S., Hu, C., Fay, J., Lee, E., Genovese, M. C.
OXFORD UNIV PRESS.2018
- **SAFETY SUMMARY RESULTS OF BARICITINIB FOCUSING ON SERIOUS INFECTIONS EVENTS AND PRESELECTED COMORBIDITIES**
Combe, B., Balsa, A., Winthrop, K., Tony, H., Genovese, M. C., Harigai, M., Smolen, J. S., Emery, P., Dudler, J., Hall, S., Zerbini, C. A., Van Den Bosch, F., Durand, et al
OXFORD UNIV PRESS.2018
- **IMPROVEMENTS IN REMISSION AND LOW DISEASE ACTIVITY ARE ACHIEVED WITH ONGOING SARILUMAB TREATMENT, IN PATIENTS WITH RHEUMATOID ARTHRITIS IN TWO PHASE III STUDIES**
Genovese, M. C., Mangan, E. K., Fay, J., Kimura, T., van Hoogstraten, H., Fleischmann, R.
OXFORD UNIV PRESS.2018
- **DURABILITY, MAINTENANCE AND EFFECTS OF DOSE REDUCTION FOLLOWING PROLONGED TREATMENT WITH BARICITINIB**
Smolen, J. S., Dougados, M., Takeuchi, T., Genovese, M. C., Haraoui, B., Klar, R., Kavanaugh, A., Alonso, R. B., Dudler, J., Taylor, P. C., Nash, P., Zerbini, C. A., Durez, et al
OXFORD UNIV PRESS.2018
- **Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes** *ARTHRITIS RESEARCH & THERAPY*
Genovese, M., Westhovens, R., Meuleners, L., Van der Aa, A., Harrison, P., Tasset, C., Kavanaugh, A.
2018; 20: 57
- **Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics.** *RMD open*
Kremer, J. M., Schiff, M., Muram, D., Zhong, J., Alam, J., Genovese, M. C.
2018; 4 (1): e000581
- **Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis** *JOURNAL OF RHEUMATOLOGY*
Keystone, E. C., Genovese, M. C., Schlichting, D. E., de la Torre, I., Beattie, S. D., Rooney, T. P., Taylor, P. C.
2018; 45 (1): 14–21

- **Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics** *RMD OPEN*
Kremer, J. M., Schiff, M., Muram, D., Zhong, J., Alam, J., Genovese, M. C.
2018; 4 (1)
- **Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis.** *Rheumatology (Oxford, England)*
Genovese, M. C., Kremer, J. M., Kartman, C. E., Schlichting, D. E., Xie, L., Carmack, T., Pantojas, C., Sanchez Burson, J., Tony, H., Macias, W. L., Rooney, T. P., Smolen, J. S.
2018; 57 (5): 900–908
- **Secukinumab in Active Rheumatoid Arthritis after Anti-TNF alpha Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study** *RHEUMATOLOGY AND THERAPY*
Tahir, H., Deodhar, A., Genovese, M., Takeuchi, T., Aelion, J., Van den Bosch, F., Haemmerle, S., Richards, H. B.
2017; 4 (2): 475–88
- **Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to TNF Inhibitors: 52-Week Results from a Phase 3 Study**
Genovese, M. C., Combe, B., Kremer, J., Adams, D., Lee, C., Kerr, L., Nash, P.
WILEY.2017
- **Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study** *ANNALS OF THE RHEUMATIC DISEASES*
Cohen, S., Genovese, M. C., Choy, E., Perez-Ruiz, F., Matsumoto, A., Pavelka, K., Pablos, J. L., Rizzo, W., Hrycaj, P., Zhang, N., Shergy, W., Kaur, P.
2017; 76 (10): 1679–87
- **Dose Reduction of Baricitinib in Patients with Rheumatoid Arthritis Achieving Sustained Disease Control: Results of a Prospective Study**
Takeuchi, T., Genovese, M. C., Haraoui, B., Li, Z., Xie, L., Klar, R., Correia, A., Ottawa, S., Lopez-Romero, P., de la Torre, I., Rooney, T. P., Smolen, J. S.
WILEY.2017
- **Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 5.5 Years: An Updated Integrated Safety Analysis**
Genovese, M. C., Smolen, J. S., Takeuchi, T., Hyslop, D., Macias, W. L., Rooney, T. P., Chen, L., Dickson, C. L., Camp, J., Cardillo, T., Ishii, T., Winthrop, K.
WILEY.2017
- **Long Term Safety of Filgotinib in the Treatment of Rheumatoid Arthritis: Week 84 Data from a Phase 2b Open-Label Extension Study**
Genovese, M. C., Kavanaugh, A., Winthrop, K., Greenwald, M., Ponce, L., Enriquez Sosa, F., Stanislavchuk, M., Mazur, M., Spindler, A., Cseuz, R., Nikulenkova, N., Glowacka-Kulesz, M., Szombati, et al
WILEY.2017
- **Efficacy and Safety of Switching from Adalimumab to Sarilumab in an Open-Label Extension of a Phase 3 Monotherapy Trial in Patients with Active Rheumatoid Arthritis**
Burmester, G. R., Fiore, S., Hu, C., Fay, J., Lee, E., Genovese, M. C.
WILEY.2017
- **The Effect of Sarilumab in Combination with Dmards on Fasting Glucose and Glycosylated Hemoglobin in Patients with Rheumatoid Arthritis with and without Diabetes**
Genovese, M. C., Fleischmann, R., Hagino, O., Hu, C., Pena-Rossi, C., Sadeh, J., Graham, N. H., Mangan, E. K., van Hoogstraten, H., Mandrup-Poulsen, T.
WILEY.2017
- **Molecular Features Define Unique Sjogren's Syndrome Patient Subsets**
James, J. A., Guthridge, J. M., Chen, H., Lu, R., Bourn, R. L., Baer, A. N., Noaiseh, G., Parke, A., Coca, A., Utset, T., Genovese, M. C., Aberle, T., Wallace, et al
WILEY.2017
- **Improvements in Remission and Low Disease Activity Are Achieved with Ongoing Sarilumab Treatment, in Patients with Rheumatoid Arthritis in 2 Phase 3 Studies**
Genovese, M. C., Mangan, E. K., Fay, J., Kimura, T., van Hoogstraten, H., Fleischmann, R.
WILEY.2017
- **Efficacy, Safety and Immunogenicity in Randomized, Double-Blind (DB) and OpenLabel Extension (OLE) Studies Comparing FKB327, an Adalimumab Biosimilar, with the Adalimumab Reference Product (Humira (R); RP) in Patients (pts) with Active Rheumatoid Arthritis (RA)**
Genovese, M. C., Glover, J., Matsunaga, N., Chisholm, D., Alten, R.
WILEY.2017

- **Duration of Response in a Phase 3 Study of Sarilumab Plus Methotrexate in Patients with Active, Moderate-to-Severe Rheumatoid Arthritis**
Genovese, M. C., Mangan, E. K., Kimura, T., Iglesias-Rodriguez, M., Huizinga, T. J.
WILEY.2017
- **Association between Clinical Response and Normalization of Patient-Reported Outcome Measures in Rheumatoid Arthritis: Post-Hoc Analysis from Two Phase 2b Filgotinib Studies**
Genovese, M. C., Van der Aa, A., Jamoul, C., Tasset, C., Harrison, P., Westhovens, R., Kavanaugh, A.
WILEY.2017
- **Correlation of Multi-Biomarker Disease Activity Score with Clinical Disease Activity Measures for the JAK1-Selective Inhibitor Filgotinib As Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients**
Genovese, M. C., Galien, R., Pan, Y., Van der Aa, A., Jamoul, C., Harrison, P., Tasset, C., Goyal, L., Li, W., Tarrant, J.
WILEY.2017
- **Long-Term Safety and Efficacy of Upadacitinib (ABT-494), an Oral JAK-1 Inhibitor in Patients with Rheumatoid Arthritis in an Open Label Extension Study**
Genovese, M. C., Kremer, J., Zhong, S., Friedman, A.
WILEY.2017
- **Transaminase Levels and Hepatic Events During Tocilizumab Treatment Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis** *ARTHRITIS & RHEUMATOLOGY*
Genovese, M. C., Kremer, J. M., van Vollenhoven, R. F., Alten, R., Jose Scali, J., Kelman, A., Dimonaco, S., Brockwell, L.
2017; 69 (9): 1751–61
- **Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial** *LANCET*
Nash, P., Kirkham, B., Okada, M., Rahman, P., Combe, B., Burmester, G., Adams, D. H., Kerr, L., Lee, C., Shuler, C. L., Genovese, M., SPIRIT-P Study Grp
2017; 389 (10086): 2317–27
- **Low immunogenicity of tocilizumab in patients with rheumatoid arthritis** *ANNALS OF THE RHEUMATIC DISEASES*
Burmester, G. R., Choy, E., Kivitz, A., Ogata, A., Bao, M., Nomura, A., Lacey, S., Pei, J., Reiss, W., Pethoe-Schramm, A., Mallalieu, N. L., Wallace, T., Michalska, et al
2017; 76 (6): 1078-1085
- **Efficacy and Safety Analysis by Overall Anti-drug Antibody Result up to Week 30 in Patients with Rheumatoid Arthritis Treated with SB2 (an Infliximab Biosimilar) or Reference Infliximab in a Phase III Study**
Choe, J., Smolen, J., Keystone, E., Genovese, M., Lee, Y., Rho, Y., Therrien, F.
J RHEUMATOL PUBL CO.2017: 872
- **Sarilumab Dose Reduction in an Open-label Extension Study in RA Patients**
Genovese, M., Fay, J., Parrino, J., Beyers, D., Iglesias-Rodriguez, M., van Hoogstraten, H., Graham, N., Boddy, A., Simon, A., Martincova, R., Burmester, G., Fiore, S.
J RHEUMATOL PUBL CO.2017: 895–96
- **Clinical and Radiographic Outcomes After 3 Years of Sarilumab in Patients with Rheumatoid Arthritis**
Genovese, M., van Adelsberg, J., van Hoogstraten, H., Iglesias-Rodriguez, M., Mangan, E., Graham, N., Jayawardena, S., Spindler, A., Fiore, S.
J RHEUMATOL PUBL CO.2017: 895
- **Impact of Anti-Drug Antibodies on Efficacy and Safety up to Week 24 from A Phase III Study Comparing SB5 (An Adalimumab Biosimilar) with Reference Adalimumab in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy**
Genovese, M., Weinblatt, M., Keystone, E., Baranauskaitė, A., Cheong, S., Ghil, J.
J RHEUMATOL PUBL CO.2017: 878
- **Efficacy of Sarilumab Plus csDMARDs in Rheumatoid Arthritis Patients who had an Inadequate Response to One or More than One Prior TNF Inhibitor**
Genovese, M., Pinheiro, G., Mangan, E., Lin, Y., van Adelsberg, J., van Hoogstraten, H., Kimura, T., Fleischmann, R., Fiore, S.
J RHEUMATOL PUBL CO.2017: 896
- **Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis** *ARTHRITIS & RHEUMATOLOGY*
Kremer, J. M., Genovese, M. C., Keystone, E., Taylor, P. C., Zuckerman, S. H., Ruotolo, G., Schlichting, D. E., Crotzer, V. L., Nantz, E., Beattie, S. D., Macias, W. L.

2017; 69 (5): 943-952

- **Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate** *ARTHRITIS & RHEUMATOLOGY*
Kivitz, A. J., Gutierrez-Urena, S. R., Pooley, J., Genovese, M. C., Kristy, R., Shay, K., Wang, X., Garg, J. P., Zubrzycka-Sienkiewicz, A.
2017; 69 (4): 709-719
- **RADIOGRAPHIC OUTCOMES IN PATIENTS ACHIEVING CLINICAL REMISSION OR LOW DISEASE ACTIVITY IN A PHASE 3 STUDY OF SARILUMAB PLUS METHOTREXATE IN PATIENTS WITH ACTIVE, MODERATE TO SEVERE RHEUMATOID ARTHRITIS**
van Hoogstraten, H., Mangan, E. K., Fay, J., van Adelsberg, J., Fan, C., Genovese, M. C.
OXFORD UNIV PRESS.2017: 204–5
- **SARILUMAB DOSE REDUCTION IN AN OPEN-LABEL EXTENSION STUDY IN RHEUMATOID ARTHRITIS PATIENTS**
Genovese, M. C., Fay, J., Parrino, J., Beyer, D., Iglesias-Rodriguez, M., Graham, N., Boddy, A., Martincova, R., Burmester, G. R.
OXFORD UNIV PRESS.2017: 139
- **CLINICAL AND RADIOGRAPHIC OUTCOMES AFTER 3 YEARS OF SARILUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS**
Genovese, M. C., van Adelsberg, J., van Hoogstraten, H., Iglesias-Rodriguez, M., Mangan, E. K., Graham, N., Spindler, A.
OXFORD UNIV PRESS.2017: 27–28
- **EFFICACY AND SAFETY OF SARILUMAB IN SUBGROUPS OF PATIENTS WITH RHEUMATOID ARTHRITIS FROM 2 PHASE 3 STUDIES**
Genovese, M. C., Fleischmann, R., Mangan, E. K., van Adelsberg, J., Iglesias-Rodriguez, M., Fan, C., Huizinga, T. W.
OXFORD UNIV PRESS.2017: 137–38
- **Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials** *RHEUMATOLOGY*
Moots, R. J., Sebba, A., Rigby, W., Ostor, A., Porter-Brown, B., Donaldson, F., Dimonaco, S., Rubbert-Roth, A., van Vollenhoven, R., Genovese, M. C.
2017; 56 (4): 541-549
- **Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)** *ANNALS OF THE RHEUMATIC DISEASES*
Smolen, J. S., Kremer, J. M., Gaich, C. L., DeLozier, A. M., Schlichting, D. E., Xie, L., Stoykov, I., Rooney, T., Bird, P., Sanchez Burson, J. M., Genovese, M. C., Combe, B.
2017; 76 (4)
- **Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis** *ANNALS OF THE RHEUMATIC DISEASES*
Burmester, G. R., Landew, R., Genovese, M. C., Friedman, A. W., Pfeifer, N. D., Varothai, N. A., Lacerda, A. P.
2017; 76 (2): 414-417
- **Peficitinib, a JAK inhibitor, in combination with limited conventional synthetic DMARDs in the treatment of moderate-to-severe rheumatoid arthritis.** *Arthritis & rheumatology (Hoboken, N.J.)*
Genovese, M. C., Greenwald, M., Coddling, C., Zubrzycka-Sienkiewicz, A., Kivitz, A. J., Wang, A., Shay, K., Wang, X., Garg, J. P., Cardiel, M. H.
2017
- **Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis.** *Arthritis & rheumatology (Hoboken, N.J.)*
Kremer, J. M., Genovese, M. C., Keystone, E., Taylor, P. C., Zuckerman, S. H., Ruotolo, G., Schlichting, D. E., Crotzer, V. L., Nantz, E., Beattie, S. D., Macias, W. L.
2017; 69 (5): 943–52
- **Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis.** *Annals of the rheumatic diseases*
Burmester, G. R., Landewé, R., Genovese, M. C., Friedman, A. W., Pfeifer, N. D., Varothai, N. A., Lacerda, A. P.
2017; 76 (2): 414–17
- **Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON).** *Annals of the rheumatic diseases*
Smolen, J. S., Kremer, J. M., Gaich, C. L., DeLozier, A. M., Schlichting, D. E., Xie, L., Stoykov, I., Rooney, T., Bird, P., Sánchez Bursón, J. M., Genovese, M. C., Combe, B.
2017; 76 (4): 694–700

- **Low immunogenicity of tocilizumab in patients with rheumatoid arthritis.** *Annals of the rheumatic diseases*
Burmester, G. R., Choy, E., Kivitz, A., Ogata, A., Bao, M., Nomura, A., Lacey, S., Pei, J., Reiss, W., Pethoe-Schramm, A., Mallalieu, N. L., Wallace, T., Michalska, et al
2017; 76 (6): 1078–85
- **Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials.** *Rheumatology (Oxford, England)*
Moots, R. J., Sebba, A., Rigby, W., Ostor, A., Porter-Brown, B., Donaldson, F., Dimonaco, S., Rubbert-Roth, A., van Vollenhoven, R., Genovese, M. C.
2016
- **Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIB Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate** *ARTHRITIS & RHEUMATOLOGY*
Genovese, M. C., Smolen, J. S., Weinblatt, M. E., Burmester, G. R., Meerwein, S., Camp, H. S., Wang, L., Othman, A. A., Khan, N., Pangan, A. L., Jungerwirth, S.
2016; 68 (12): 2857-2866
- **Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings.** *Annals of the rheumatic diseases*
Genovese, M. C., Yang, F., Østergaard, M., Kinnman, N.
2016; 75 (11): 1979-1983
- **Development of the American College of Rheumatology's Rheumatoid Arthritis Electronic Clinical Quality Measures** *ARTHRITIS CARE & RESEARCH*
Yazdany, J., Robbins, M., Schmajuk, G., DeSai, S., Lacaille, D., Neogi, T., Singh, J. A., Genovese, M., Myslinski, R., Fisk, N., Francisco, M., Newman, E.
2016; 68 (11): 1579-1590
- **Peficitinib, a JAK inhibitor, in the treatment of moderate-to-severe rheumatoid arthritis in methotrexate-inadequate responders.** *Arthritis & rheumatology*
Kivitz, A. J., Gutierrez-Ureña, S. R., Poiley, J., Genovese, M. C., Kristy, R., Shay, K., Wang, X., Garg, J. P., Zubrzycka-Sienkiewicz, A.
2016
- **Increased pretreatment serum IFN- γ ratio predicts non-response to tumour necrosis factor inhibition in rheumatoid arthritis** *ANNALS OF THE RHEUMATIC DISEASES*
Muskardin, T. W., Vashisht, P., Dorschner, J. M., Jensen, M. A., Chrobot, B. S., Kern, M., Curtis, J. R., Danila, M. I., Cofield, S. S., Shadick, N., Nigrovic, P. A., St Clair, E. W., Bingham, et al
2016; 75 (10): 1757-1762
- **Dual Cytokine Inhibition with ABT-122, a Tnf- and IL-17-Targeted Dual Variable Domain Immunoglobulin (DVD-Ig (TM)): Results from a 24-Week Open-Label Extension Study in Patients with Rheumatoid Arthritis**
Genovese, M. C., Weinblatt, M., Mansikka, H. T., Peloso, P. M., Chen, K., Li, Y., Liu, J., Padley, R. J.
WILEY.2016
- **Clinical and Radiographic Outcomes after 3 Years of Sarilumab in Patients with Rheumatoid Arthritis**
van der Heijde, D., van Adelsberg, J., van Hoogstraten, H., Iglesias-Rodriguez, M., Mangan, E., Graham, N., Dukovic, D., Spindler, A., Genovese, M. C.
WILEY.2016
- **Efficacy and Safety of Sarilumab in Subgroups of Patients with Rheumatoid Arthritis from 2 Phase 3 Studies**
Genovese, M. C., Fleischmann, R., Mangan, E., van Adelsberg, J., Iglesias-Rodriguez, M., Dukovic, D., Fan, C., Huizinga, T. J.
WILEY.2016
- **The Effect of Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor on Patient-Reported Outcomes: Results from Two 24-Week Phase 2B Dose Ranging Studies**
Genovese, M. C., Westhovens, R., Kavanaugh, A., Meuleners, L., Van der Aa, A., Harrison, P., Tasset, C.
WILEY.2016
- **Olokizumab Treatment of Both Western and Asian Patients with Rheumatoid Arthritis Who Have Failed Anti-TNF Treatment Results in Sustained Improvements in Patient-Reported Outcomes**
Genovese, M. C., Durez, P., Fleischmann, R., Tanaka, Y., Furst, D. E., Yamanaka, H., Vasyutin, I., Kaviarasu, T., Korneva, E., Koloda, D., Takeuchi, T.
WILEY.2016
- **Effects of Baseline Patient Characteristics on Baricitinib Efficacy in Patients with Rheumatoid Arthritis**
Kremer, J. M., Genovese, M. C., Muram, D., Zhong, J., Alam, J., Schiff, M.
WILEY.2016

- **ABT-122, a Tnf- and IL-17-Targeted Dual Variable Domain (DVD)-Ig (TM) in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Results from a Phase 2 Trial**
Genovese, M. C., Weinblatt, M., Aelion, J. A., Mansikka, H. T., Peloso, P. M., Chen, K., Li, Y., Othman, A. A., Khatri, A., Khan, N. S., Padley, R. J.
WILEY.2016
- **Safety and Efficacy of ABT-122, a TNF and IL-17-Targeted Dual Variable Domain (DVD)-Ig (TM), in Psoriatic Arthritis Patients with Inadequate Response to Methotrexate: Results from a Phase 2 Trial**
Mease, P. J., Genovese, M. C., Weinblatt, M., Peloso, P. M., Chen, K., Li, Y., Mansikka, H. T., Khatri, A., Othman, A. A., Wishart, N., Liu, J., Padley, R. J.
WILEY.2016
- **Pooled Safety and Efficacy of Sarilumab in Rheumatoid Arthritis Patients 65 Years of Age and Older**
Fleischmann, R., Genovese, M. C., van Adelsberg, J., Mangan, E., Iglesias-Rodriguez, M., Dukovic, D., Huizinga, T. J.
WILEY.2016
- **Sarilumab Dose Reduction in an Open-Label Extension Study in RA Patients**
Genovese, M. C., Fay, J., Parrino, J., Beyer, D., Iglesias-Rodriguez, M., Graham, N., Boddy, A., Simon, J., Martincova, R., Burmester, G. R.
WILEY.2016
- **Efficacy after Transition to SB5 from Reference Adalimumab (Humira (R)) Vs. Continuation of SB5 or Reference Adalimumab By Antibodies Developed after Transition from a SB5 Phase III Study**
Genovese, M. C., Weinblatt, M., Keystone, E. C., Baranaskaite, A., Cheong, S., Ghil, J.
WILEY.2016
- **Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis** *ARTHRITIS RESEARCH & THERAPY*
Genovese, M. C., Van Vollenhoven, R. F., Wilkinson, B., Wang, L., Zwillich, S. H., Gruben, D., Biswas, P., Riese, R., Takiya, L., Jones, T. V.
2016; 18
- **Baricitinib, an Oral Janus Kinase (JAK) 1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to TNF Inhibitors: Results of the Phase 3 RA-BEACON Study**
Genovese, M., Kremer, J., Zamani, O., Ludivico, C., Krogulec, M., Xie, L., Beattie, S., Koch, A., Cardillo, T., Rooney, T., Macias, W., Schlichting, D., Smolen, et al
J RHEUMATOL PUBL CO.2016: 1188
- **Clinical and Radiographic Efficacy of Sarilumab Plus Methotrexate in Biologic-Experienced and Biologic-Naive Patients with Rheumatoid Arthritis in a Phase 3, Randomized, Double-blind, Placebo-Controlled Study**
Fiore, S., Genovese, M., Fan, C., Decktor, D., Fleischmann, R.
J RHEUMATOL PUBL CO.2016: 1217
- **Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept** *BMC MUSCULOSKELETAL DISORDERS*
Alten, R., Bingham, C. O., Cohen, S. B., Curtis, J. R., Kelly, S., Wong, D., Genovese, M. C.
2016; 17
- **Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials** *CLINICAL AND EXPERIMENTAL RHEUMATOLOGY*
Wallenstein, G. V., Kanik, K. S., Wilkinson, B., Cohen, S., Cutolo, M., Fleischmann, R., Genovese, M. C., Gomez Reino, J., Gruben, D., Kremer, J., Krishnaswami, S., Lee, E. B., Pascual-Ramos, et al
2016; 34 (3): 430-442
- **Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials.** *Clinical and experimental rheumatology*
Wallenstein, G. V., Kanik, K. S., Wilkinson, B., Cohen, S., Cutolo, M., Fleischmann, R., Genovese, M. C., Gomez reino, J., Gruben, D., Kremer, J., Krishnaswami, S., Lee, E. B., Pascual-Ramos, et al
2016; 34 (3): 430-442
- **SARILUMAB DOSE REDUCTION TO MANAGE LABORATORY ABNORMALITIES IN AN OPEN-LABEL EXTENSION STUDY IN RA PATIENTS**
Burmester, G. R., Garg, A., Van Hoogstraten, H., Graham, N., Boddy, A., Parrino, J., Genovese, M. C.
WILEY-BLACKWELL.2016: 40-41
- **IMMUNOGENICITY OF SUBCUTANEOUS AND INTRAVENOUS TOCILIZUMAB AS MONOTHERAPY OR IN COMBINATION WITH DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS**

- Genovese, M. C., Ogata, A., Nomura, A., Bao, M., Hitraya, E., Lacey, S., Burmester, G. R.
OXFORD UNIV PRESS.2016: 92-93
- **EFFICACY AND SAFETY OF SARILUMAB PLUS METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS USING BIOLOGICS AND IN THOSE WHO ARE BIOLOGIC-NAIVE**
Fleischmann, R., Genovese, M., Fan, C., Fiore, S., Decktor, D.
LIPPINCOTT WILLIAMS & WILKINS.2016: 122
 - **Baricitinib in Patients with Refractory Rheumatoid Arthritis** *NEW ENGLAND JOURNAL OF MEDICINE*
Genovese, M. C., Kremer, J., Zamani, O., Ludivico, C., Krogulec, M., Xie, L., Beattie, S. D., Koch, A. E., Cardillo, T. E., Rooney, T. P., Macias, W. L., de Bono, S., Schlichting, et al
2016; 374 (13): 1243-1252
 - **Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis.** *journal of rheumatology*
Genovese, M. C., Braun, D. K., Erickson, J. S., Berclaz, P., Banerjee, S., Heffernan, M. P., Carlier, H.
2016; 43 (2): 289-297
 - **Improvement in Psoriasis Signs and Symptoms Assessed by the Psoriasis Symptom Inventory with Brodalumab Treatment in Patients with Psoriatic Arthritis.** *journal of rheumatology*
Mease, P. J., Genovese, M. C., Mutebi, A., Viswanathan, H. N., Chau, D., Feng, J., Erondy, N., Nirula, A.
2016; 43 (2): 343-349
 - **Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD Trial.** *journal of rheumatology*
Keystone, E. C., Genovese, M. C., Hall, S., Bae, S., Han, C., Gathany, T. A., Xu, S., Zhou, Y., Leu, J. H., Hsia, E. C.
2016; 43 (2): 298-306
 - **VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis.** *Arthritis & rheumatology (Hoboken, N.J.)*
Genovese, M. C., van Vollenhoven, R. F., Pacheco-Tena, C., Zhang, Y., Kinnman, N.
2016; 68 (1): 46-55
 - **VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis** *ARTHRITIS & RHEUMATOLOGY*
Genovese, M. C., Van Vollenhoven, R. F., Pacheco-Tena, C., Zhang, Y., Kinnman, N.
2016; 68 (1): 46-55
 - **Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial.** *Arthritis research & therapy*
Strand, V., Kosinski, M., Chen, C., Joseph, G., Rendas-Baum, R., Graham, N. M., van Hoogstraten, H., Bayliss, M., Fan, C., Huizinga, T., Genovese, M. C.
2016; 18: 198-?
 - **Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis** *RHEUMATOLOGY*
Burmester, G. R., Durez, P., Shestakova, G., Genovese, M. C., Schulze-Koops, H., Li, Y., Wang, Y. A., Lewitzky, S., Koroleva, I., Berneis, A. A., Lee, D. M., Hueber, W.
2016; 55 (1): 49-55
 - **Reliability and Validity of the Psoriasis Symptom Inventory in Patients With Psoriatic Arthritis** *ARTHRITIS CARE & RESEARCH*
Wilson, H. D., Mutebi, A., Revicki, D. A., Mease, P. J., Genovese, M. C., Erondy, N., Nirula, A., Yuan, F. J., Viswanathan, H. N.
2015; 67 (12): 1750-1756
 - **OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy** *ANNALS OF THE RHEUMATIC DISEASES*
Taylor, P. C., Genovese, M. C., Greenwood, M., Ho, M., Nasonov, E., Oemar, B., Stoilov, R., Vencovsky, J., Weinblatt, M.
2015; 74 (12): 2123-2129
 - **Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy.** *journal of rheumatology*
Genovese, M. C., Hsia, E., Belkowsky, S. M., Chien, C., Masterson, T., Thurmond, R. L., Manthey, C. L., Yan, X. D., Ge, T., Franks, C., Greenspan, A.

2015; 42 (10): 1752-1760

- **The Clinical Efficacy and Safety of Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, in Primary Sjogren's Syndrome: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Trial**
St Clair, E., Baer, A. N., Noaiseh, G., Parke, A., Coca, A., Utset, T., Genovese, M. C., Wallace, D. J., McNamara, J., Boyle, K., Keyes-Elstein, L., Franchimont, N., James, et al
WILEY-BLACKWELL.2015
- **Characterization of Changes in Lymphocyte Subsets in Baricitinib-Treated Patients with Rheumatoid Arthritis in Two Phase 3 Studies**
Emery, P., McInnes, I., Genovese, M. C., Smolen, J. S., Kremer, J., Dougados, M., Schlichting, D. E., Rooney, T., Issa, M., de Bono, S., Macias, W. L., Rogai, V., Zuckerman, et al
WILEY-BLACKWELL.2015
- **Sarilumab Dose Reduction to Manage Laboratory Abnormalities in an Open-Label Extension Study in RA Patients**
Burmester, G., Garg, A., van Hoogstraten, H., Graham, N., Boddy, A., Parrino, J., Genovese, M. C.
WILEY-BLACKWELL.2015
- **Previous Biologic Disease-Modifying Antirheumatic Drug (bDMARD) Exposure and Efficacy and Safety Analysis from a Phase 3 Study of Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitors**
Genovese, M. C., Kremer, J. M., Kartman, C., Schlichting, D. E., Xie, L., Carmack, T., Macias, W. L., Smolen, J. S.
WILEY-BLACKWELL.2015
- **Telomere Damage in Rheumatoid Arthritis**
Li, Y., Ju, J., Bush, T. M., Genovese, M. C., Goronzy, J., Weyand, C. M.
WILEY-BLACKWELL.2015
- **Two-Year Clinical Response to Brodalumab, an Anti-Interleukin-17 Receptor Antibody, in Patients with Psoriatic Arthritis**
Genovese, M. C., Mease, P. J., Greenwald, M., Ritchlin, C. T., Beaulieu, A., Deodhar, A. A., Newmark, R., Feng, J., Erondu, N., Nirula, A.
WILEY-BLACKWELL.2015
- **Randomized, Double-Blind, Phase 3 Study of Efficacy and Safety of ABP 501 Compared with Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis**
Cohen, S. B., Genovese, M. C., Choy, E. H., Perez-Ruiz, F., Pablos, J. L., Zhang, N., Kaur, P.
WILEY-BLACKWELL.2015
- **Responder Rates and Numbers Needed to Treat Based on Clinically Meaningful Improvements in Patient Reported Outcomes (PROs) Including Health-Related Quality of Life (HRQoL) after Sarilumab Treatment during a Phase III Randomized Controlled Trial (RCT)**
Strand, V., Rendas-Baum, R., Joseph, G. J., Chen, C., van Hoogstraten, H., Huizinga, T. J., Genovese, M. C.
WILEY-BLACKWELL.2015
- **Immunogenicity of Subcutaneous and Intravenous Tocilizumab As Monotherapy or in Combination with Dmards**
Genovese, M. C., Ogata, A., Nomura, A., Bao, M., Hitraya, E., Lacey, S., Burmester, G.
WILEY-BLACKWELL.2015
- **Efficacy of Sarilumab Plus Methotrexate in Achieving Clinical Remission, Using 4 Different Definitions, in Patients with Active, Moderate-to-Severe Rheumatoid Arthritis in a Phase 3 Study**
Genovese, M. C., Stanislav, M., van Hoogstraten, H., Martincova, R., Fan, C., van Adelsberg, J.
WILEY-BLACKWELL.2015
- **Switching from Intravenous to Subcutaneous Formulation of Abatacept: Different Results in a Series of 21 Patients** *JOURNAL OF RHEUMATOLOGY*
Genovese, M.
2015; 42 (10): 1994
- **Response to Baricitinib at 4 Weeks Predicts Response at 12 and 24 Weeks in Patients with Rheumatoid Arthritis: Results from Two Phase 3 Studies**
Kremer, J., Dougados, M., Genovese, M. C., Emery, P., Yang, L., de Bono, S., Holzkaemper, T., Iikuni, N., Schlichting, D. E., Smolen, J. S.
WILEY-BLACKWELL.2015
- **Increases in Serum Cholesterol with Baricitinib Treatment are Associated with Favorable Changes in Apolipoprotein Content and with Improvement in DAS28-CRP in Patients with Rheumatoid Arthritis**
Magloire, A., Kremer, J., Genovese, M. C., Keystone, E., Taylor, P., Zuckerman, S. H., Schlichting, D. E., Nantz, E., Beattie, S. D., Macias, W. L.
E M H SWISS MEDICAL PUBLISHERS LTD.2015: 4S

- **Safety and Efficacy of Baricitinib through 128 Weeks in an Open-Label, Long- Term Extension Study in Patients with Rheumatoid Arthritis**
Magloire, A., Keystone, E., Taylor, P., Genovese, M., Schlichting, D., de la Torre, I., Beattie, S., Rooney, T.
E M H SWISS MEDICAL PUBLISHERS LTD.2015: 4S–5S
- **Efficacy and Safety of Tabalumab, an Anti-B-Cell-Activating Factor Monoclonal Antibody, in a Heterogeneous Rheumatoid Arthritis Population Results From a Randomized, Placebo-Controlled, Phase 3 Trial (FLEX-O)** *JCR-JOURNAL OF CLINICAL RHEUMATOLOGY*
Genovese, M. C., Silverman, G. J., Emery, P., Gupta, R. C., Gill, A., Veenhuizen, M., Xie, L., Komocsar, W. J., Berclaz, P., Lee, C.
2015; 21 (5): 231-238
- **Apremilast in Patients With Active Rheumatoid Arthritis: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study** *ARTHRITIS & RHEUMATOLOGY*
Genovese, M. C., Jarosova, K., Cieslak, D., Alper, J., Kivitz, A., Hough, D. R., Maes, P., Pineda, L., Chen, M., Zaidi, F.
2015; 67 (7): 1703-1710
- **Increases in Serum Cholesterol with Baricitinib Treatment are Associated with Favorable Changes in Apolipoprotein Content and with Improvement in DAS28-CRP in Patients with Rheumatoid Arthritis**
Kremer, J., Genovese, M., Keystone, E., Taylor, P., Zuckerman, S., Schlichting, D., Nantz, E., Beattie, S., Macias, W.
J RHEUMATOL PUBL CO.2015: 1291
- **Safety and Efficacy of Baricitinib through 128 Weeks in an Open-Label, Long-Term Extension Study in Patients with Rheumatoid Arthritis**
Keystone, E., Taylor, P., Genovese, M., Schlichting, D., de la Torre, I., Beattie, S., Rooney, T.
J RHEUMATOL PUBL CO.2015: 1292
- **Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis** *ARTHRITIS RESEARCH & THERAPY*
Chakravarty, E. F., Martyanov, V., Fiorentino, D., Wood, T. A., Haddon, D. J., Jarrell, J. A., Utz, P. J., Genovese, M. C., Whitfield, M. L., Chung, L.
2015; 17
- **Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study.** *Arthritis & rheumatology*
Genovese, M. C., Fleischmann, R., Kivitz, A. J., Rell-Bakalarska, M., Martincova, R., Fiore, S., Rohane, P., van Hoogstraten, H., Garg, A., Fan, C., van Adelsberg, J., Weinstein, S. P., Graham, et al
2015; 67 (6): 1424-1437
- **Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate Results of a Phase III Study** *ARTHRITIS & RHEUMATOLOGY*
Genovese, M. C., Fleischmann, R., Kivitz, A. J., Rell-Bakalarska, M., Martincova, R., Fiore, S., Rohane, P., van Hoogstraten, H., Garg, A., Fan, C., van Adelsberg, J., Weinstein, S. P., Graham, et al
2015; 67 (6): 1424-1437
- **Mass cytometry as a platform for the discovery of cellular biomarkers to guide effective rheumatic disease therapy** *ARTHRITIS RESEARCH & THERAPY*
Nair, N., Mei, H. E., Chen, S., Hale, M., Nolan, G. P., Maecker, H. T., Genovese, M., Fathman, C. G., Whiting, C. C.
2015; 17
- **Results of a proof of concept, double-blind, randomized trial of a second generation antisense oligonucleotide targeting high-sensitivity C-reactive protein (hs-CRP) in rheumatoid arthritis** *ARTHRITIS RESEARCH & THERAPY*
Warren, M. S., Hughes, S. G., Singleton, W., Yamashita, M., Genovese, M. C.
2015; 17: 80
- **Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate** *ANNALS OF THE RHEUMATIC DISEASES*
Keystone, E. C., Taylor, P. C., Drescher, E., Schlichting, D. E., Beattie, S. D., Berclaz, P., Lee, C. H., Fidelus-Gort, R. K., Luchi, M. E., Rooney, T. P., Macias, W. L., Genovese, M. C.
2015; 74 (2): 333-340
- **Reliability and Validity of the Psoriasis Symptom Inventory in Patients With Psoriatic Arthritis.** *Arthritis care & research*
Wilson, H. D., Mutebi, A., Revicki, D. A., Mease, P. J., Genovese, M. C., Erondy, N., Nirula, A., Yuan, F. J., Viswanathan, H. N.
2015; 67 (12): 1750–56
- **Mass cytometry as a platform for the discovery of cellular biomarkers to guide effective rheumatic disease therapy.** *Arthritis research & therapy*
Nair, N., Mei, H. E., Chen, S., Hale, M., Nolan, G. P., Maecker, H. T., Genovese, M., Fathman, C. G., Whiting, C. C.

2015; 17: 127-?

- **Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis.** *Arthritis research & therapy*
Chakravarty, E. F., Martyanov, V., Fiorentino, D., Wood, T. A., Haddon, D. J., Jarrell, J. A., Utz, P. J., Genovese, M. C., Whitfield, M. L., Chung, L.
2015; 17: 159-?
- **Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate Results From a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study** *ARTHRITIS & RHEUMATOLOGY*
Weinblatt, M. E., Genovese, M. C., Ho, M., Hollis, S., Rosiak-Jedrychowicz, K., Kavanaugh, A., Millson, D. S., Leon, G., Wang, M., van der Heijde, D.
2014; 66 (12): 3255-3264
- **A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of 2 Dosing Regimens of Fostamatinib in Patients with Rheumatoid Arthritis with an Inadequate Response to a Tumor Necrosis Factor-alpha Antagonist** *JOURNAL OF RHEUMATOLOGY*
Genovese, M. C., van der Heijde, D. M., Keystone, E. C., Spindler, A. J., Benhamou, C., Kavanaugh, A., Fudman, E., Lampl, K., O'Brien, C., Duffield, E. L., Poiley, J., Weinblatt, M. E.
2014; 41 (11): 2120-2128
- **A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-alpha antagonist.** *journal of rheumatology*
Genovese, M. C., van der Heijde, D. M., Keystone, E. C., Spindler, A. J., Benhamou, C., Kavanaugh, A., Fudman, E., Lampl, K., O'Brien, C., Duffield, E. L., Poiley, J., Weinblatt, M. E.
2014; 41 (11): 2120-2128
- **Serum 14-3-3 eta is a Novel Marker that Complements Current Serological Measurements to Enhance Detection of Patients with Rheumatoid Arthritis** *JOURNAL OF RHEUMATOLOGY*
Maksymowych, W. P., Naides, S. J., Bykerk, V., Siminovitch, K. A., van Schaardenburg, D., Boers, M., Landewe, R., van der Heijde, D., Tak, P., Genovese, M. C., Weinblatt, M. E., Keystone, E. C., Zhukov, et al
2014; 41 (11): 2104-2113
- **Clinical Response in Subjects with Psoriatic Arthritis Following One Year of Treatment with Brodalumab, an Anti-Interleukin-17 Receptor Antibody**
Genovese, M. C., Mease, P., Greenwald, M. W., Ritchlin, C. T., Beaulieu, A., Deodhar, A. A., Newmark, R., Feng, J., Erond, N., Nirula, A.
WILEY-BLACKWELL.2014: S687
- **Impact of Sarilumab on Health Related Quality of Life (HRQoL), Fatigue, and Sleep in Rheumatoid Arthritis Patients at Week 24-Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study.**
Strand, V., Joseph, G., van Hoogstraten, H., Chen, C., Fan, C., Carita, P., Graham, N., Momtahan, T., Genovese, M. C.
WILEY-BLACKWELL.2014: S669-S670
- **Comparable Efficacy with Sarilumab Plus Methotrexate in Biologic-Experienced and Biologic-Naive Patients with Moderate-to-Severe Rheumatoid Arthritis from a Phase 3, Randomized, Double-Blind, Placebo-Controlled, International Study.**
Fleischmann, R., Decktor, D. L., Fan, C., Van Hoogstraten, H., Genovese, M. C.
WILEY-BLACKWELL.2014: S1232-S1233
- **Increases in Serum Cholesterol with Baricitinib Treatment Are Associated with Favorable Changes in Apolipoprotein Content and with Improvement in DAS28-CRP in Patients with Rheumatoid Arthritis**
Kremer, J. M., Genovese, M. C., Keystone, E. C., Taylor, P. C., Zuckerman, S. H., Schlichting, D. E., Nantz, E. P., Beattie, S. D., Macias, W. L.
WILEY-BLACKWELL.2014: S210
- **Reliability and Construct Validity of the Psoriasis Symptom Inventory in Subjects with Psoriatic Arthritis.**
Mease, P., Genovese, M. C., Mutebi, A., Wilson, H., Revicki, D., Erond, N., Nirula, A., Feng, J., Viswanathan, H.
WILEY-BLACKWELL.2014: S240
- **A Profile of the Efficacy of Sarilumab Plus Methotrexate in Rheumatoid Arthritis Patients: Results of a 52-Week, Phase 3, Randomized, Double-Blind, Placebo-Controlled, International Study.**
Kavanaugh, A., Decktor, D. L., Fan, C., van Adelsberg, J., Martincova, R., Genovese, M. C.
WILEY-BLACKWELL.2014: S1233-S1234
- **Impact of Golimumab on Physical Function and Employability of Patients with Rheumatoid Arthritis: 5-Year Data from 3 Phase III Clinical Trials**
Han, C., Keystone, E. C., Fleischmann, R., Smolen, J. S., Matteson, E. L., Emery, P., Genovese, M. C., Gathany, T. A., Hsia, E. C.
WILEY-BLACKWELL.2014: S1090

- **A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Not on Concomitant Methotrexate.**
Genovese, M. C., Greenwald, M., Coddling, C., Cardiel, M. H., Zubrzycka-Sienkiewicz, A., Kivitz, A. J., Wisseh, S., Shay, K., Garg, J. P.
WILEY-BLACKWELL.2014: S1234-S1235
- **Reversibility of pharmacodynamic effects after short and long-term treatment with tofacitinib in patients with rheumatoid arthritis.**
Genovese, M. C., Kawabata, T. T., Soma, K., Menon, S., Clark, J. D., Hodge, J. A., Takiya, L., Riese, R., Krishnaswami, S.
WILEY-BLACKWELL.2014: E225-E226
- **Safety and Efficacy of Baricitinib through 128 Weeks in an Open-Label, Long-Term Extension Study in Patients with Rheumatoid Arthritis.**
Keystone, E. C., Taylor, P. C., Genovese, M. C., Schlichting, D. E., De La Torre, I., Beattie, S. D., Rooney, T.
WILEY-BLACKWELL.2014: S1232
- **Sarilumab, a fully human monoclonal antibody against IL-6R alpha in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial** *ANNALS OF THE RHEUMATIC DISEASES*
Huizinga, T. W., Fleischmann, R. M., Jasson, M., Radin, A. R., van Adelsberg, J., Fiore, S., Huang, X., Yancopoulos, G. D., Stahl, N., Genovese, M. C.
2014; 73 (9): 1626-1634
- **Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study** *ANNALS OF THE RHEUMATIC DISEASES*
Genovese, M. C., Fleischmann, R., Furst, D., Janssen, N., Carter, J., Dasgupta, B., Bryson, J., Duncan, B., Zhu, W., Pitzalis, C., Durez, P., Kretsos, K.
2014; 73 (9): 1607-1615
- **Long-Term Safety of Subcutaneous Abatacept in Rheumatoid Arthritis Integrated Analysis of Clinical Trial Data Representing More Than Four Years of Treatment** *ARTHRITIS & RHEUMATOLOGY*
Alten, R., Kaine, J., Keystone, E., Nash, P., Delaet, I., Genovese, M. C.
2014; 66 (8): 1987-1997
- **A Phase II Randomized Study of Subcutaneous Ixekizumab, an Anti-Interleukin-17 Monoclonal Antibody, in Rheumatoid Arthritis Patients Who Were Naive to Biologic Agents or Had an Inadequate Response to Tumor Necrosis Factor Inhibitors** *ARTHRITIS & RHEUMATOLOGY*
Genovese, M. C., Greenwald, M., Cho, C., Berman, A., Jin, L., Cameron, G. S., Benichou, O., Xie, L., Braun, D., Berclaz, P., Banerjee, S.
2014; 66 (7): 1693-1704
- **Long-Term Safety of Tocilizumab in Patients with Rheumatoid Arthritis following a Mean Treatment Duration of 3.9 Years**
Haraoui, B., Sebba, A., Rubbert-Roth, A., Scali, J., Alten, R., Kremer, J., Pitts, L., Vernon, E., van Vollenhoven, R., Genovese, M.
J RHEUMATOL PUBL CO.2014: 1508
- **12- and 24-Week Patient-Reported Outcomes from a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis**
Chalabi, Y., Smolen, J., Taylor, P., Genovese, M., Lee, C., Schlichting, D., Macias, W., Keystone, E.
J RHEUMATOL PUBL CO.2014: 1498-99
- **Baricitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: 52 Week Safety and Efficacy in an Open-Label, Long-Term Extension Study**
Baker, M., Chalabi, Y., Genovese, M., Taylor, P., Schlichting, D., Beattie, S., Macias, W., Keystone, E.
J RHEUMATOL PUBL CO.2014: 1505
- **Magnetic Resonance Imaging Substudy in a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis**
Chalabi, Y., Peterfy, C., Genovese, M., Emery, P., Taylor, P., Schlichting, D., Beattie, S., Macias, W., Keystone, E.
J RHEUMATOL PUBL CO.2014: 1506
- **Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis** *NEW ENGLAND JOURNAL OF MEDICINE*
Mease, P. J., Genovese, M. C., Greenwald, M. W., Ritchlin, C. T., Beaulieu, A. D., Deodhar, A., Newmark, R., Feng, J., Erondy, N., Nirula, A.
2014; 370 (24): 2295-2306
- **Subcutaneous Abatacept for the Treatment of Rheumatoid Arthritis: Longterm Data from the ACQUIRE Trial.** *journal of rheumatology*
Genovese, M. C., Tena, C. P., Covarrubias, A., Leon, G., Mysler, E., Keiserman, M., Valente, R., Nash, P., Simon-Campos, J. A., Box, J., Legerton, C. W., Nasonov, E., Durez, et al
2014; 41 (4): 629-639

- **SUSTAINED IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE, WORK PRODUCTIVITY, EMPLOYABILITY AND REDUCED HEALTHCARE RESOURCE UTILIZATION OF PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS TREATED WITH GOLIMUMAB: 5-YEAR RESULTS FROM THREE PHASE III STUDIES**
Han, C., Kavanaugh, A., Genovese, M. C., Deodhar, A., Hsu, B., Hsia, E.
OXFORD UNIV PRESS.2014: 74
- **FINAL 5-YEAR SAFETY AND EFFICACY RESULTS OF A PHASE 3, RANDOMIZED PLACEBO-CONTROLLED TRIAL OF GOLIMUMAB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE**
Keystone, E., Genovese, M. C., Hall, S., Miranda, P. C., Bae, S., Han, C., Gathany, T., Zhou, Y., Xu, S., Hsia, E. C.
OXFORD UNIV PRESS.2014: 99
- **Prevalence and risk factors for Staphylococcus aureus colonization in individuals entering maximum-security prisons** *EPIDEMIOLOGY AND INFECTION*
Mukherjee, D. V., Herzig, C. T., Jeon, C. Y., Lee, C. J., Apa, Z. L., Genovese, M., Gage, D., Koenigsmann, C. J., Lowy, F. D., Larson, E. L.
2014; 142 (3): 484-493
- **BARICITINIB, AN ORAL JANUS KINASE INHIBITOR, IN THE TREATMENT OF RHEUMATOID ARTHRITIS: SAFETY AND EFFICACY IN AN OPEN-LABEL, LONG-TERM EXTENSION STUDY**
Taylor, P., Genovese, M., Keystone, E., Schlichting, D., Beattie, S., Macias, W.
BMJ PUBLISHING GROUP.2014: A31
- **One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study.** *journal of rheumatology*
Genovese, M. C., Durez, P., Richards, H. B., Supronik, J., Dokoupilova, E., Aelion, J. A., Lee, S., Codding, C. E., Kellner, H., Ikawa, T., Hugot, S., Ligozio, G., Mpofu, et al
2014; 41 (3): 414-421
- **Effect of golimumab on carotid atherosclerotic disease measures and cardiovascular events in inflammatory arthritides.** *Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases*
Wasko, M. C., Hsia, E. C., Kirkham, B., Touboul, P., Fleischmann, R., Genovese, M. C., Matteson, E. L., Lu, J., Xu, W., Rahman, M. U.
2014; 20 (1): 1-10
- **Effects of golimumab, an anti-tumour necrosis factor-alpha human monoclonal antibody, on lipids and markers of inflammation** *ANNALS OF THE RHEUMATIC DISEASES*
Kirkham, B. W., Wasko, M. C., Hsia, E. C., Fleischmann, R. M., Genovese, M. C., Matteson, E. L., Liu, H., Rahman, M. U.
2014; 73 (1): 161-169
- **A Phase 2b, 12-Week Study of VX-509, an Oral Selective Janus Kinase 3 Inhibitor, in Combination with Background Methotrexate in Rheumatoid Arthritis**
Genovese, M. C., van Vollenhoven, R., Bloom, B. J., Jiang, J. G., Kinnman, N.
WILEY-BLACKWELL.2013: 3320
- **Oskira-2: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To Disease-Modifying Antirheumatic Drugs.**
Dawes, P., Domic, A., Genovese, M. C., van der Heijde, D., Jenkins, M., O'Brien, C., Oemar, B., Vencovsky, J., Weinblatt, M.
WILEY-BLACKWELL.2013: S198-S199
- **Sustained Improvement In Health-Related Quality Of Life, Work Productivity, Employability, and Reduced Healthcare Resource Utilization Of Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Treated With Golimumab: 5-Year Results From 3 Phase III Studies**
Han, C., Kavanaugh, A., Genovese, M. C., Hsu, B., Deodhar, A. A., Hsia, E. C.
WILEY-BLACKWELL.2013: S137
- **Results Of 64 Weeks Of Treatment With An Anti-IL-17 Antibody, Ixekizumab, In Patients With Rheumatoid Arthritis In a Phase 2 Study**
Genovese, M. C., Carlier, H., Erickson, J., Braun, D., Banerjee, S.
WILEY-BLACKWELL.2013: S188
- **Clinical Response To Brodalumab, An Anti-Interleukin-17 Receptor Antibody, In Subjects With Psoriatic Arthritis**
Genovese, M. C., Mease, P. J., Greenwald, M. W., Ritchlin, C. T., Beaulieu, A., Deodhar, A., Newmark, R., Feng, J., Erondy, N., Nirula, A.
WILEY-BLACKWELL.2013: S347-S348
- **Efficacy and Safety Of Subcutaneous Administration Of Tabalumab, An Anti-B Cell Activating Factor Monoclonal Antibody, In Rheumatoid Arthritis: Results From a Phase 3 Multicenter, Randomized, Double-Blind Study**

- Genovese, M. C., Silverman, G. J., Emery, P., Gupta, R., Gill, A., Komocsar, W. J., Veenhuizen, M., Xie, L., Berclaz, P., Lee, C.
WILEY-BLACKWELL.2013: S733–S734
- **Final 5-Year Safety and Efficacy Results Of a Phase 3, Randomized Placebo-Controlled Trial Of Golimumab In Patients With Active Rheumatoid Arthritis Despite Prior Treatment With Methotrexate**
Keystone, E., Genovese, M. C., Hall, S., Miranda, P., Bae, S., Han, C., Gathany, T. A., Zhou, Y., Xu, S., Hsia, E. C.
WILEY-BLACKWELL.2013: S597–S598
 - **Prediction Of TNF Inhibitor Response In Rheumatoid Arthritis Patients Using Single Cell Network Profiling Of Intracellular Immune Signaling**
Ptacek, J., Hawtin, R., Louie, B., Evensen, E., Cordeiro, J., Mittleman, B., Atallah, M., Cesano, A., Bingham, C. O., Cofield, S., Curtis, J. R., Danila, M. I., Furie, et al
WILEY-BLACKWELL.2013: S375
 - **Lack Of Early Clinical Response To Treatment With Baricitinib Predicts Low Probability Of Achieving Long Term DAS28-ESR Low Disease Activity Or Remission In Patients With Rheumatoid Arthritis.**
Keystone, E., Genovese, M. C., Taylor, P., Zhu, B., Beattie, S. D., de Bono, S., Rooney, T., Schlichting, D. E., Macias, W.
WILEY-BLACKWELL.2013: S607
 - **Effect Of Brodalumab (AMG 827) On Pain and Physical Functioning In Patients With Psoriatic Arthritis**
Genovese, M. C., Mease, P. J., Viswanathan, H., Chau, D., Feng, J., Erondu, N., Nirula, A.
WILEY-BLACKWELL.2013: S136
 - **Novel Biomarkers From Peripheral Blood Mononuclear Cells Indicate Disease Activity In Rheumatoid Arthritis Patients.**
Ptacek, J., Hawtin, R., Louie, B., Evensen, E., Cordeiro, J., Mittleman, B., Atallah, M., Cesano, A., Bingham, C. O., Cofield, S., Curtis, J. R., Danila, M. I., Furie, et al
WILEY-BLACKWELL.2013: S974–S975
 - **Oskira-3: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To a Tumor Necrosis Factor-alpha Antagonist.**
Genovese, M., van der Heijde, D., Keystone, E., Spindler, A., Benhamou, C., Kavanaugh, A., Fudman, E., Lampl, K., O'Brien, C., Duffield, E., Pooley, J., Weinblatt, M.
WILEY-BLACKWELL.2013: S199–S200
 - **Disease Activity in Moderate and Severe Rheumatoid Arthritis At Discontinuation in 10-Year Open-Label Extension Studies With Etanercept**
Weinblatt, M. E., Bathon, J. M., Hooper, M., Bitman, B., Yang, Y., Collier, D. H., Chung, J., Genovese, M. C.
WILEY-BLACKWELL.2013: S986–S987
 - **Transaminase Levels and Hepatic Events Observed During Tocilizumab Treatment: Pooled Analysis Of Long-Term Clinical Trial Safety Data In Patients With Rheumatoid Arthritis.**
Genovese, M. C., Kremer, J. M., van Vollenhoven, R. F., Alten, R., Jose Scali, J., Kelman, A., Rowell, L., Pitts, L.
WILEY-BLACKWELL.2013: S201
 - **A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate** *ANNALS OF THE RHEUMATIC DISEASES*
Genovese, M. C., Lee, E., Satterwhite, J., Veenhuizen, M., Disch, D., Berclaz, P., Myers, S., Sides, G., Benichou, O.
2013; 72 (9): 1453-1460
 - **Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors** *ANNALS OF THE RHEUMATIC DISEASES*
Genovese, M. C., Fleischmann, R. M., Greenwald, M., Satterwhite, J., Veenhuizen, M., Xie, L., Berclaz, P., Myers, S., Benichou, O.
2013; 72 (9): 1461-1468
 - **Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis A Randomized Trial** *ANNALS OF INTERNAL MEDICINE*
Kremer, J., Li, Z., Hall, S., Fleischmann, R., Genovese, M., Martin-Mola, E., Isaacs, J. D., Gruben, D., Wallenstein, G., Krishnaswami, S., Zwillich, S. H., Koncz, T., Riese, et al
2013; 159 (4): 253-?
 - **Novel small molecule therapeutics in rheumatoid arthritis** *RHEUMATOLOGY*
Kelly, V., Genovese, M.
2013; 52 (7): 1155-1162

- **Golimumab in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results Through 2 Years of the GO-FORWARD Study Extension** *JOURNAL OF RHEUMATOLOGY*
Keystone, E. C., Genovese, M. C., Hall, S., Miranda, P. C., Bae, S., Palmer, W., Wu, Z., Xu, S., Hsia, E. C.
2013; 40 (7): 1097-1103
- **Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure** *JOURNAL OF RHEUMATOLOGY*
Genovese, M. C., Rubbert-Roth, A., Smolen, J. S., Kremer, J., Khraishi, M., Gomez-Reino, J., Sebba, A., Pilon, R., Williams, S., van Vollenhoven, R.
2013; 40 (6): 768-780
- **Validation of Remission of Rheumatoid Arthritis by Traditional Disease Activity Score and Provisional Criteria by American College of Rheumatology and European League Against Rheumatism: Analysis Based on Patient Reported Outcomes Analyzed from 3 Phase III Golimumab Clinical Trials of Golimumab**
Keystone, E., Han, C., Fleischmann, R., Smolen, J., Emery, P., Genovese, M., Doyle, M., Hsia, E.
J RHEUMATOL PUBL CO.2013: 968-69
- **Longterm Remission with Golimumab in Active Rheumatoid Arthritis Patients Despite Methotrexate Through 2 Years**
Keystone, E., Genovese, M., Klareskog, L., Xu, S., Han, C., Hsia, E.
J RHEUMATOL PUBL CO.2013: 968
- **Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study.** *Annals of the rheumatic diseases*
Genovese, M. C., Durez, P., Richards, H. B., Supronik, J., Dokoupilova, E., Mazurov, V., Aelion, J. A., Lee, S., Codding, C. E., Kellner, H., Ikawa, T., Hugot, S., Mpofu, et al
2013; 72 (6): 863-869
- **Efficacy and Safety of Belimumab in Patients with Rheumatoid Arthritis: A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study** *JOURNAL OF RHEUMATOLOGY*
Stohl, W., Merrill, J. T., McKay, J. D., Lisse, J. R., Zhong, Z. J., Freimuth, W. W., Genovese, M. C.
2013; 40 (5): 579-589
- **Immunogenicity, Safety, and Efficacy of Abatacept Administered Subcutaneously With or Without Background Methotrexate in Patients With Rheumatoid Arthritis: Results From a Phase III, International, Multicenter, Parallel-Arm, Open-Label Study** *ARTHRITIS CARE & RESEARCH*
Nash, P., Nayiager, S., Genovese, M. C., Kivitz, A. J., Oelke, K., Ludivico, C., Palmer, W., Rodriguez, C., Delaet, I., Elegbe, A., Corbo, M.
2013; 65 (5): 718-728
- **Effects of Fostamatinib (R788), an Oral Spleen Tyrosine Kinase Inhibitor, on Health-related Quality of Life in Patients with Active Rheumatoid Arthritis: Analyses of Patient-reported Outcomes from a Randomized, Double-blind, Placebo-controlled Trial** *JOURNAL OF RHEUMATOLOGY*
Weinblatt, M. E., Kavanaugh, A., Genovese, M. C., Jones, D. A., Musser, T. K., Grossbard, E. B., Magilavy, D. B.
2013; 40 (4): 369-378
- **LONG-TERM SAFETY OF TOCILIZUMAB IN RA PATIENTS TREATED FOR A MEAN DURATION OF 3.7 YEARS**
Genovese, M., Sebba, A., Rubbert-Roth, A., Scali, J. J., Alten, R., Kremer, J. M., Pitts, L., Vernon, E., van Vollenhoven, R. F.
OXFORD UNIV PRESS.2013: 93-94
- **VALIDATION OF REMISSION OF RHEUMATOID ARTHRITIS BY TRADITIONAL DISEASE ACTIVITY SCORE AND PROVISIONAL CRITERIA BY AMERICAN COLLEGE OF RHEUMATOLOGY AND EUROPEAN LEAGUE AGAINST RHEUMATISM: ANALYSIS BASED ON PATIENT-REPORTED OUTCOMES ANALYSED FROM THREE PHASE III GOLIMUMAB CLINICAL TRIALS**
Han, C., Keystone, E. C., Fleischmann, R., Smolen, J., Emery, P., Genovese, M., Doyle, M., Hsia, E. C.
OXFORD UNIV PRESS.2013: 83
- **WEEKLY SUBCUTANEOUS ABATACEPT CONFERS COMPARABLE ONSET OF TREATMENT RESPONSE AND MAGNITUDE OF EFFICACY IMPROVEMENT OVER 6 MONTHS WHEN ADMINISTERED WITH OR WITHOUT AN INTRAVENOUS ABATACEPT LOADING DOSE** *Annual Meeting of the British-Society-for-Rheumatology and British-Health-Professionals-in-Rheumatology*
Schiff, M., Alten, R., Weinblatt, M. E., Nash, P., Fleischmann, R., Durez, P., Kaine, J., Delaet, I., Kelly, S., Maldonado, M., Patel, S., Genovese, M.
OXFORD UNIV PRESS.2013: 91-92
- **Tabalumab in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate and Naive to Biologic Therapy: A Phase II, Randomized, Placebo-Controlled Trial** *ARTHRITIS AND RHEUMATISM*
Genovese, M. C., Bojin, S., Biagini, I. M., Mociran, E., Cristei, D., Mirea, G., Georgescu, L., Sloan-Lancaster, J.
2013; 65 (4): 880-889

- **24-WEEK RESULTS OF A BLINDED PHASE IIB DOSE-RANGING STUDY OF BARICITINIB, AN ORAL JAK1/JAK2 INHIBITOR, IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS** *Annual Meeting of the British-Society-for-Rheumatology and British-Health-Professionals-in-Rheumatology*
Taylor, P., Genovese, M., Keystone, E. C., Drescher, E., Berclaz, P., Lee, C., Fidelus-Gort, R., Schlichting, D., Beattie, S., Luchi, M., Macias, W.
OXFORD UNIV PRESS.2013: 44–45
- **Tocilizumab as Monotherapy or in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs: Twenty-Four-Week Results of an Open-Label, Clinical Practice Study** *ARTHRITIS CARE & RESEARCH*
Weinblatt, M. E., Kremer, J., Cush, J., Rigby, W., Teng, L. L., Devenport, J., Singh, N., Lepley, D., Genovese, M. C.
2013; 65 (3): 362-371
- **Effects of sclerostin antibody on healing of a non-critical size femoral bone defect** *JOURNAL OF ORTHOPAEDIC RESEARCH*
Jawad, M. U., Fritton, K. E., Ma, T., Ren, P., Goodman, S. B., Ke, H. Z., Babij, P., Genovese, M. C.
2013; 31 (1): 155-163
- **Magnetic Resonance Imaging Substudy in a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis.** *Annual Scientific Meeting of the American-College-of-Rheumatology (ACR) and Association-of-Rheumatology-Health-Professionals (ARHP)*
Peterfy, C. G., Emery, P., Genovese, M. C., Keystone, E., Taylor, P., Berclaz, P., Dicarlo, J. C., Lee, C. H., Schlichting, D. E., Beattie, S. D., Luchi, M. E., Macias, W.
WILEY-BLACKWELL.2012: S1050–S1051
- **Efficacy, safety and tolerability of HZT-501, including users of low-dose aspirin (LDA), a single-tablet combination of ibuprofen-famotidine: results of two phase 3 trials.**
Weinblatt, M., Genovese, M. C., Kivitz, A., Bello, A. E., Grahn, A., Sherman, J. W., Schiff, M. H., Magelli, M.
WILEY-BLACKWELL.2012: E203
- **Long-Term Safety of Tocilizumab in Patients with Rheumatoid Arthritis and a Mean Treatment Duration of 3.7 Years.**
Genovese, M. C., Sebba, A., Rubbert-Roth, A., Jose Scali, J., Alten, R., Kremer, J. M., Pitts, L., Vernon, E., van Vollenhoven, R. F.
WILEY-BLACKWELL.2012: S700–S701
- **Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Inhibitor of the IL-6 Receptor: Effects On Hemoglobin Levels in a Clinical Trial for the Treatment of Moderate-to-Severe Rheumatoid Arthritis**
Genovese, M. C., Fleischmann, R. M., Jasson, M., Radin, A. R., Hamilton, J., Huizinga, T. J.
WILEY-BLACKWELL.2012: S568
- **Gene Expression Profiling and Pathway Changes Associated with Clinical Response to Tadalumab Blockade of Membrane Bound and Soluble B Cell Activating Factor in Rheumatoid Arthritis**
Komocsar, W. J., Genovese, M. C., Dow, E. R., Banerjee, P., Penny, M. A., Nantz, E. P., Stepanians, S., Ho, A., Berclaz, P., Hoffman, R. W.
WILEY-BLACKWELL.2012: S565
- **Validation of Remission of Rheumatoid Arthritis by Traditional Disease Activity Score and Provisional Criteria by American College of Rheumatology and European League Against Rheumatism: Patient Reported Outcomes Analyzed From 3 Phase III Golimumab Trials.**
Han, C., Keystone, E., Fleischmann, R., Smolen, J. S., Emery, P., Genovese, M. C., Doyle, M. K., Hsia, E. C.
WILEY-BLACKWELL.2012: S35–S36
- **12-and 24-Week Patient-Reported Outcomes From a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis** *Annual Scientific Meeting of the American-College-of-Rheumatology (ACR) and Association-of-Rheumatology-Health-Professionals (ARHP)*
Smolen, J. S., Schlichting, D. E., Sterling, K. L., Keystone, E., Taylor, P., Genovese, M. C., Johnson, L., Rizo Rodriguez, J. C., Lee, C. H., Gaich, C. L.
WILEY-BLACKWELL.2012: S214–S214
- **24-Week Results of a Blinded Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis.** *Annual Scientific Meeting of the American-College-of-Rheumatology (ACR) and Association-of-Rheumatology-Health-Professionals (ARHP)*
Genovese, M. C., Keystone, E., Taylor, P., Drescher, E., Berclaz, P., Lee, C. H., Schlichting, D. E., Beattie, S. D., Fidelus-Gort, R. K., Luchi, M. E., Macias, W.
WILEY-BLACKWELL.2012: S1049–S1050
- **Prolonged Exposure to Subcutaneous and Intravenous Abatacept in Patients with Rheumatoid Arthritis Does Not Affect Rates of Infection, Malignancy and Autoimmune Events: Results From Pooled Clinical Trial Data.** *Annual Scientific Meeting of the American-College-of-Rheumatology (ACR) and Association-of-Rheumatology-Health-Professionals (ARHP)*
Genovese, M. C., Hochberg, M. C., Cohen, R. B., Weinblatt, M. E., Kaine, J., Keystone, E., Nash, P., Delaet, I., Alten, R.

WILEY-BLACKWELL.2012: S725–S725

- **Subcutaneous Abatacept: Long-Term Data From the Acquire Trial** *Annual Scientific Meeting of the American-College-of-Rheumatology (ACR) and Association-of-Rheumatology-Health-Professionals (ARHP)*
Genovese, M. C., Pacheco-Tena, C., Covarrubias, A., LEON, G., Mysler, E., Keiserman, M., Valente, R., Nash, P., Simon-Campos, J. A., Box, J., Legerton, C., Nasonov, E., Durez, et al
WILEY-BLACKWELL.2012: S201–S201
- **Longterm Safety and Efficacy of Abatacept Through 5 Years of Treatment in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitor Therapy** *JOURNAL OF RHEUMATOLOGY*
Genovese, M. C., Schiff, M., Luggen, M., Le Bars, M., Aranda, R., Elegbe, A., DougadoS, M.
2012; 39 (8): 1546-1554
- **Effect of Golimumab on Patient-reported Outcomes in Rheumatoid Arthritis: Results from the GO-FORWARD Study** *JOURNAL OF RHEUMATOLOGY*
Genovese, M. C., Han, C., Keystone, E. C., Hsia, E. C., Buchanan, J., Gathany, T., Murphy, F. T., Wu, Z., Parasuraman, S., Rahman, M. U.
2012; 39 (6): 1185-1191
- **SAFETY PROFILE OF SUBCUTANEOUS ABATACEPT FOCUSING ON CLINICALLY RELEVANT EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND UP TO 4.5 YEARS OF EXPOSURE** *Annual Meeting of the British-Society-for-Rheumatology*
Alten, R., Kaine, J. L., Keystone, E., Nash, P. T., Delaet, I., Qi, K., Genovese, M. C.
OXFORD UNIV PRESS.2012: 127–128
- **SUBCUTANEOUS ABATACEPT VERSUS INTRAVENOUS ABATACEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS: LONG-TERM DATA FROM THE ACQUIRE TRIAL**
Genovese, M. C., Covarrubias Cobos, A., Leon, G., Mysler, E. F., Keiserman, M. W., Valente, R. M., Nash, P. T., Simon Campos, J., Porawska, W., Box, J. H., Legerton, C. W., Nasonov, E. L., Durez, et al
OXFORD UNIV PRESS.2012: 128–29
- **SECUKINUMAB TREATMENT PROVIDES SUSTAINED RESPONSE OVER ONE YEAR IN PATIENTS WITH RHEUMATOID ARTHRITIS**
Durez, P., Genovese, M. C., Richards, H. B., Supronik, J., Dokoupilova, E., Aelion, J. A., Lee, S., Codding, C. E., Kellner, H., Ikawa, T., Hugot, S., Ligozio, G., Mpofo, et al
OXFORD UNIV PRESS.2012: 29
- **LONG-TERM SAFETY OF TOCILIZUMAB IN RHEUMATOID ARTHRITIS CLINICAL TRIALS**
Genovese, M. C., Sebba, A., Rubbert-Roth, A., Scali, J., Zilberstein, M., Thompson, L., Van Vollenhoven, R.
OXFORD UNIV PRESS.2012: 75–76
- **Effect of golimumab combined with methotrexate on radiographic progression in rheumatoid arthritis: comment on the article by Emery et al** *Reply* *ARTHRITIS AND RHEUMATISM*
Emery, P., Conaghan, P. G., Fleischmann, R., van der Heijde, D., Keystone, E. C., Genovese, M. C., Hsia, E. C., Xu, W., Beutler, A., Baratelle, A., Rahman, M. U.
2012; 64 (4): 1298–99
- **Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs** *ARTHRITIS AND RHEUMATISM*
Fleischmann, R., Cutolo, M., Genovese, M. C., Lee, E. B., Kanik, K. S., Sadis, S., Connell, C. A., Gruben, D., Krishnaswami, S., Wallenstein, G., Wilkinson, B. E., Zwillich, S. H.
2012; 64 (3): 617-629
- **Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: Results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial** *ARTHRITIS AND RHEUMATISM*
Tak, P. P., Mease, P. J., Genovese, M. C., Kremer, J., Haraoui, B., Tanaka, Y., Bingham, C. O., Ashrafzadeh, A., Travers, H., Safa-Leathers, S., Kumar, S., Dummer, W.
2012; 64 (2): 360-370
- **IL-17 receptor and its functional significance in psoriatic arthritis** *MOLECULAR AND CELLULAR BIOCHEMISTRY*
Raychaudhuri, S. P., Raychaudhuri, S. K., Genovese, M. C.
2012; 359 (1-2): 419–29
- **Exploratory analyses of the association of MRI with clinical, laboratory and radiographic findings in patients with rheumatoid arthritis** *ANNALS OF THE RHEUMATIC DISEASES*
Emery, P., van der Heijde, D., Ostergaard, M., Conaghan, P. G., Genovese, M. C., Keystone, E. C., Fleischmann, R., Hsia, E. C., Xu, W., Xu, S., Rahman, M. U.
2011; 70 (12): 2126-2130

- **Sarilumab for the Treatment of Moderate-to-Severe Rheumatoid Arthritis: Results of a Phase 2, Randomized, Double-Blind, Placebo-Controlled, International Study**
Genovese, M. C., Kivitz, A. J., Simon Campos, J., Rell-Bakalarska, M., Fleischmann, R. M., Jasson, M., Radin, A. R., Huang, X., Huizinga, T. J.
WILEY-BLACKWELL.2011: 4041–42
- **Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial** *ANNALS OF THE RHEUMATIC DISEASES*
Conaghan, P. G., Emery, P., Ostergaard, M., Keystone, E. C., Genovese, M. C., Hsia, E. C., Xu, W., Rahman, M. U.
2011; 70 (11): 1968-1974
- **Tofacitinib (CP-690,550) in Combination with Traditional Disease-Modifying Anti-Rheumatic Drugs: Phase 3 Study Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis and An Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs.** *75th Annual Scientific Meeting of the American-College-of-Rheumatology/46th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals (ARHP)*
Strand, V., Kremer, J. M., Li, Z. G., Hall, S., Fleischmann, R. M., Genovese, M. C., Martin-Mola, E., Isaacs, J., Gruben, D., Wallenstein, G., Krishnaswami, S., Zwillich, S. H., Koncz, et al
WILEY-BLACKWELL.2011: S1032–S1032
- **American College of Rheumatology hybrid measure for assessing efficacy of treatment in patients with refractory rheumatoid arthritis: comment on the article by Genovese et al Reply** *ARTHRITIS AND RHEUMATISM*
Genovese, M. C.
2011; 63 (10): 3182
- **Tocilizumab Monotherapy and Tocilizumab Plus Disease-Modifying Antirheumatic Drugs in a US Rheumatoid Arthritis Population with Inadequate Response to Anti-Tumor Necrosis Factor Agents.**
Weinblatt, M. E., Kremer, J. M., Cush, J. J., Rigby, W., Teng, L., Singh, N., Malamet, R. L., Genovese, M. C.
WILEY-BLACKWELL.2011: S162
- **Longer-Term Safety of Fostamatinib (R788) in Patients with Rheumatoid Arthritis-Analysis of Clinical Trial Data From up to 2 Years of Exposure.**
Kavanaugh, A., Weinblatt, M. E., Genovese, M. C., Musser, T. K., Grossbard, E. B., Magilavy, D. B., Hollis, S., van-Sway, E., Millson, D.
WILEY-BLACKWELL.2011: S1018–S1019
- **Effects of the Oral SYK Inhibitor, Fostamatinib (R788), on Health-Related Quality of Life in a Phase II Study of Active Rheumatoid Arthritis.**
Weinblatt, M. E., Kavanaugh, A., Genovese, M. C., Jones, D. A., Musser, T. K., Grossbard, E. B., Magilavy, D. B.
WILEY-BLACKWELL.2011: S158–S159
- **Long-Term Safety of Tocilizumab in Rheumatoid Arthritis Clinical Trials.**
Genovese, M. C., Sebba, A., Rubbert-Roth, A., Scali, J., Zilberstein, M., Thompson, L., van Vollenhoven, R. F.
WILEY.2011: S866
- **One Year Efficacy and Safety Results of a Phase II Trial of Secukinumab in Patients with Rheumatoid Arthritis.**
Genovese, M. C., Durez, P., Richards, H. B., Supronik, J., Dokoupilova, E., Aelion, J. A., Lee, S., Codding, C. E., Kellner, H., Ikawa, T., Hugot, S., Ligozio, G., Mpofo, et al
WILEY-BLACKWELL.2011: S149–S150
- **Immunogenicity Is Low and Transient with Intravenous (IV) Abatacept Therapy: Results From a Large Pooled Analysis of 3985 Patients (pts) with Rheumatoid Arthritis (RA) and up to 8 Years' Exposure**
Weinblatt, M. E., Genovese, M. C., Schiff, M. H., Westhovens, R., Alten, R., Delaet, I., Nys, M., Manning, J., Kremer, J. M.
WILEY-BLACKWELL.2011: S854
- **A Phase 2 Study of Multiple Subcutaneous Doses of LY2439821, An Anti-IL-17 Monoclonal Antibody, in Patients with Rheumatoid Arthritis in Two Populations: Naive to Biologic Therapy or Inadequate Responders to Tumor Necrosis Factor Alpha Inhibitors.** *75th Annual Scientific Meeting of the American-College-of-Rheumatology/46th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals (ARHP)*
Genovese, M. C., Greenwald, M. W., Cho, C. S., Berman, A., Jin, L., Cameron, G., Xie, L., Braun, D., Banerjee, S., Warner, L.
WILEY-BLACKWELL.2011: S1017–S1017
- **Safety Profile of Subcutaneous Abatacept Focusing on Clinically Relevant Events in Patients with Rheumatoid Arthritis (RA) and up to 4.5 Years of Exposure.** *75th Annual Scientific Meeting of the American-College-of-Rheumatology/46th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals (ARHP)*
Alten, R., Kaine, J. L., Keystone, E., Nash, P. T., Delaet, I., Qi, K., Genovese, M. C.
WILEY-BLACKWELL.2011: S150–S151

- **Subcutaneous (SC) Abatacept (ABA) Versus Intravenous (IV) ABA in Patients (pts) with Rheumatoid Arthritis: Long-Term Data From the ACQUIRE (Abatacept Comparison of Sub[QU]cutaneous versus Intravenous in Inadequate Responders to Methotrexate) Trial.** *75th Annual Scientific Meeting of the American-College-of-Rheumatology/46th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals (ARHP)*
Genovese, M. C., Covarrubias Cobos, A., Leon, G., Mysler, E. F., Keiserman, M. W., Valente, R. M., Nash, P. T., Simon Campos, J. A., Porawska, W., Box, J. H., Legerton, C. W., Nasonov, E. L., Durez, et al
WILEY-BLACKWELL.2011: S150-S150
- **Subcutaneous Abatacept Versus Intravenous Abatacept A Phase IIIb Noninferiority Study in Patients With an Inadequate Response to Methotrexate** *ARTHRITIS AND RHEUMATISM*
Genovese, M. C., Covarrubias, A., LEON, G., Mysler, E., Keiserman, M., Valente, R., Nash, P., Simon-Campos, J. A., PORAWSKA, W., Box, J., Legerton, C., Nasonov, E., Durez, et al
2011; 63 (10): 2854-2864
- **Atacept in Patients With Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Antagonist Therapy Results of a Phase II, Randomized, Placebo-Controlled, Dose-Finding Trial** *ARTHRITIS AND RHEUMATISM*
Genovese, M. C., Kinnman, N., de La Bourdonnaye, G., Rossi, C. P., Tak, P. P.
2011; 63 (7): 1793-1803
- **A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469, a p38 Mitogen-activated Protein Kinase Inhibitor, in Patients with Active Rheumatoid Arthritis** *JOURNAL OF RHEUMATOLOGY*
Genovese, M. C., Cohen, S. B., Wofsy, D., Weinblatt, M. E., Firestein, G. S., Brahn, E., Strand, V., Baker, D. G., Tong, S. E.
2011; 38 (5): 846-854
- **The Effects of Golimumab on Radiographic Progression in Rheumatoid Arthritis Results of Randomized Controlled Studies of Golimumab Before Methotrexate Therapy and Golimumab After Methotrexate Therapy** *ARTHRITIS AND RHEUMATISM*
Emery, P., Fleischmann, R., van der Heijde, D., Keystone, E. C., Genovese, M. C., Conaghan, P. G., Hsia, E. C., Xu, W., Baratte, A., Beutler, A., Rahman, M. U.
2011; 63 (5): 1200-1210
- **THE EFFICACY AND SAFETY OF SUBCUTANEOUS (SC) ABATACEPT (ABA) IS CONSISTENT WITH THE ESTABLISHED INTRAVENOUS (IV) PROFILE IN A STUDY OF 1457 PATIENTS WITH RA AND AN INADEQUATE RESPONSE TO MTX (MTX-IR)**
Nash, P., Genovese, M., COVARRUBIAS, J., LEON, G., Mysler, E., Keiserman, M., Valente, R., Simon, J., PORAWSKA, W., Box, J., Legerton, C., Nasonov, E., Durez, et al
WILEY-BLACKWELL.2011: 16-16
- **THE EFFICACY AND SAFETY OF SUBCUTANEOUS (SC) ABATACEPT (ABA) WITH OR WITHOUT MTX IN PATIENTS WITH ACTIVE RA**
Nash, P., Nayiager, S., Genovese, M., Rodriguez, C., Delaet, I., Elegbe, A., Corbo, M., Bamford, T.
WILEY-BLACKWELL.2011: 15-15
- **SAFETY, EFFICACY AND HEALTH-RELATED QUALITY OF LIFE THROUGH 5 YEARS OF ABATACEPT TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO ANTI-TUMOUR NECROSIS FACTOR THERAPY** *Annual Meeting of the British-Society-for-Rheumatology 2011*
Genovese, M. C., Schiff, M., Luggen, M., Le Bars, M., Becker, J., Aranda, R., Li, T., Elegbe, A., DougadoS, M.
OXFORD UNIV PRESS.2011: 123-123
- **SAFETY OF SUBSEQUENT BIOLOGIC THERAPY IN RA PATIENTS WHO DISCONTINUED RITUXIMAB**
Genovese, M. C., Breedveld, F. C., Emery, P., Cohen, S. B., Keystone, E., Matteson, E. L., Burke, L., Chai, A., Reiss, W., Sweetser, M., Shaw, T.
OXFORD UNIV PRESS.2011: 126
- **LONG-TERM EXTENSION STUDIES OF TOCILIZUMAB IN RA: SAFETY AND TOLERABILITY**
Genovese, M. C., Sebba, A., Rubbert-Roth, A., Scali, J., Zilberstein, M., Vernon, E., Vollenhoven, R.
OXFORD UNIV PRESS.2011: 33
- **Abatacept in the Treatment of Patients With Psoriatic Arthritis** *ARTHRITIS AND RHEUMATISM*
Mease, P., Genovese, M. C., Gladstein, G., Kivitz, A. J., Ritchlin, C., Tak, P. P., Wollenhaupt, J., Bahary, O., Becker, J., Kelly, S., Sigal, L., Teng, J., Gladman, et al
2011; 63 (4): 939-948
- **Safety and Efficacy of Etanercept Beyond 10 Years of Therapy in North American Patients With Early and Longstanding Rheumatoid Arthritis** *ARTHRITIS CARE & RESEARCH*
Weinblatt, M. E., Bathon, J. M., Kremer, J. M., Fleischmann, R. M., Schiff, M. H., Martin, R. W., Baumgartner, S. W., Park, G. S., Mancini, E. L., Genovese, M. C.
2011; 63 (3): 373-382

- **An Oral Syk Kinase Inhibitor in the Treatment of Rheumatoid Arthritis A Three-Month Randomized, Placebo-Controlled, Phase II Study in Patients With Active Rheumatoid Arthritis That Did Not Respond to Biologic Agents** *ARTHRITIS AND RHEUMATISM*
Genovese, M. C., Kavanaugh, A., Weinblatt, M. E., Peterfy, C., DiCarlo, J., White, M. L., O'Brien, M., Grossbard, E. B., Magilavy, D. B.
2011; 63 (2): 337-345
- **An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis.** *NEW ENGLAND JOURNAL OF MEDICINE*
Weinblatt, M. E., Kavanaugh, A., Genovese, M. C., Musser, T. K., Grossbard, E. B., Magilavy, D. B.
2010; 363 (14): 1303-1312
- **Edward D. Harris, Jr., MD, 1937-2010 IN MEMORIAM** *ARTHRITIS AND RHEUMATISM*
Genovese, M. C., Moynihan, E. M.
2010; 62 (9): 2623-24
- **Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate** *ANNALS OF THE RHEUMATIC DISEASES*
Cohen, S. B., Keystone, E., Genovese, M. C., Emery, P., Peterfy, C., Tak, P. P., Cravets, M., Shaw, T., Hagerty, D.
2010; 69 (6): 1158-1161
- **Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study** *ANNALS OF THE RHEUMATIC DISEASES*
Keystone, E., Genovese, M. C., Klareskog, L., Hsia, E. C., Hall, S., Miranda, P. C., Pazdur, J., Bae, S., Palmer, W., Xu, S., Rahman, M. U.
2010; 69 (6): 1129-1135
- **LY2439821, a Humanized Anti-Interleukin-17 Monoclonal Antibody, in the Treatment of Patients With Rheumatoid Arthritis A Phase I Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study** *ARTHRITIS AND RHEUMATISM*
Genovese, M. C., Van den Bosch, F., ROBERSON, S. A., Bojin, S., Biagini, I. M., Ryan, P., Sloan-Lancaster, J.
2010; 62 (4): 929-939
- **AN ASSESSMENT OF THE SERIOUS INFECTION RATE IN RITUXIMAB-TREATED RHEUMATOID ARTHRITIS (RA) PATIENTS WHO SUBSEQUENTLY RECEIVED OTHER BIOLOGIC THERAPIES: A FOLLOW-UP FROM RITUXIMAB CLINICAL TRIALS**
Genovese, M. C., Breedveld, F. C., Emery, P., Cohen, S. B., Keystone, E. C., Matteson, E. L., Burke, L. S., Chai, A., Reiss, W. G., Sweetser, M. T., Shaw, T. M.
OXFORD UNIV PRESS.2010: 14
- **IMPACT OF GOLIMUMAB ON PHYSICAL FUNCTION, HEALTH-RELATED QOL, PRODUCTIVITY AND EMPLOYMENT IN RA PATIENTS: WEEK 52 RESULTS FROM GO-FORWARD**
Genovese, M. C., Rubbert, A., Keystone, E. C., Hsia, E. C., Buchanan, J., Klareskog, L., Murphy, F. T., Wu, Z., Parasuraman, S., Rahman, M. U., GO-FORWARD Investigators
OXFORD UNIV PRESS.2010: 1109-1110
- **EFFICACY OF GOLIMUMAB, A HUMAN ANTI-TNF alpha ANTIBODY, BY BASELINE CRP LEVEL IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM THREE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES**
Emery, P., Genovese, M. C., Fleischmann, R. M., Matteson, E. L., Hsia, E. C., Xu, S., Doyle, M. K., Rahman, M. U., GO-BEFORE GO-FORWARD, GO-AFTER Investigators
OXFORD UNIV PRESS.2010: 1101
- **Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study** *ANNALS OF THE RHEUMATIC DISEASES*
Jones, G., Sebba, A., Gu, J., Lowenstein, M. B., CALVO, A., Gomez-Reino, J. J., Siri, D. A., Tomsic, M., Alecock, E., Woodworth, T., Genovese, M. C.
2010; 69 (1): 88-96
- **Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study** *ARTHRITIS RESEARCH & THERAPY*
Visvanathan, S., Rahman, M. U., Keystone, E., Genovese, M., Klareskog, L., Hsia, E., Mack, M., Buchanan, J., Elashoff, M., Wagner, C.
2010; 12 (6)
- **Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients** *ANNALS OF THE RHEUMATIC DISEASES*
Genovese, M. C., Breedveld, F. C., Emery, P., Cohen, S., Keystone, E., Matteson, E. L., Baptiste, Y., Chai, A., Burke, L., Reiss, W., Sweetser, M., Shaw, T. M.
2009; 68 (12): 1894-1897
- **Epitope-Specific Immunotherapy of Rheumatoid Arthritis Clinical Responsiveness Occurs With Immune Deviation and Relies on the Expression of a Cluster of Molecules Associated With T Cell Tolerance in a Double-Blind, Placebo-Controlled, Pilot Phase II Trial** *ARTHRITIS AND RHEUMATISM*

- Koffeman, E. C., Genovese, M., Amox, D., Keogh, E., Santana, E., Matteson, E. L., Kavanaugh, A., Molitor, J. A., Schiff, M. H., Posever, J. O., Bathon, J. M., Kivitz, A. J., Samodal, et al
2009; 60 (11): 3207-3216
- **The AMBITION Study: Superiority Of Tocilizumab vs Methotrexate Monotherapy in Patients with Rheumatoid Arthritis**
Khraishi, M., Jones, G., Genovese, M.
J RHEUMATOL PUBL CO.2009: 2574-75
 - **Safety of Other Biologic Therapies Following Rituximab Treatment in RA Patients**
Khraishi, M., Genovese, M. C., Breedveld, F.
J RHEUMATOL PUBL CO.2009: 2598-99
 - **The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial** *ANNALS OF THE RHEUMATIC DISEASES*
Schiff, M., Pritchard, C., Huffstutter, J. E., Rodriguez-Valverde, V., Durez, P., Zhou, X., Li, T., Bahrt, K., Kelly, S., Le Bars, M., Genovese, M. C.
2009; 68 (11): 1708-1714
 - **Independent Predictors for the Development of Upper Gastrointestinal Ulcers: Results from Two 24-Week Double-Blind Trials of a Single-Tablet Combination of Ibuprofen-Famotidine vs. Ibuprofen Alone**
Laine, L., Schiff, M., Genovese, M., Kivitz, A., Bello, A., Grahn, A., Walbert, T., Weinblatt, M.
NATURE PUBLISHING GROUP.2009: S535-S536
 - **First Report of Idiopathic Granulomatous Mastitis Treated with Methotrexate Monotherapy** *JOURNAL OF RHEUMATOLOGY*
Schmajuk, G., Genovese, M. C.
2009; 36 (7): 1559-1560
 - **Less Radiographic Progression with Adalimumab Plus Methotrexate Versus Methotrexate Monotherapy Across the Spectrum of Clinical Response in Early Rheumatoid Arthritis** *JOURNAL OF RHEUMATOLOGY*
Emery, P., Genovese, M. C., van Vollenhoven, R., Sharp, J. T., Patra, K., Sasso, E. H.
2009; 36 (7): 1429-1441
 - **Golimumab, a human antibody to tumour necrosis factor alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study** *ANNALS OF THE RHEUMATIC DISEASES*
Keystone, E. C., Genovese, M. C., Klareskog, L., Hsia, E. C., Hall, S. T., Miranda, P. C., Pazdur, J., Bae, S., Palmer, W., ZRUBEK, J., Wiekowski, M., Visvanathan, S., Wu, et al
2009; 68 (6): 789-796
 - **Efficacy of a p38 mitogen activated protein kinase inhibitor in mitigating an established inflammatory reaction to polyethylene particles in vivo.** *Journal of biomedical materials research. Part A*
Ma, T., Ren, P., Larsen, D. M., Suenaga, E., Zilber, S., Genovese, M., Smith, R. L., Goodman, S. B.
2009; 89 (1): 117-123
 - **CONTINUED INHIBITION OF STRUCTURAL DAMAGE IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH RITUXIMAB AT 2 YEARS: REFLEX STUDY**
Cohen, S. B., Keystone, E. C., Genovese, M., Emery, P., Peterfy, C., Tak, P., Cravets, M. W., Shaw, T., Hagerty, D.
OXFORD UNIV PRESS.2009: I88
 - **GOLIMUMAB ADMINISTERED SUBCUTANEOUSLY EVERY 4 WEEKS IN ACTIVE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE: WEEK 24 RESULTS OF GO-FORWARD STUDY**
Rubbert, A., Keystone, E., Genovese, M., Klareskog, L., Hsia, E. C., Zrubek, J., Wu, Z., Rahman, M. U., GO-FORWARD Study Investigators
OXFORD UNIV PRESS.2009: I92
 - **SAFETY OF OTHER BIOLOGIC THERAPIES FOLLOWING RITUXIMAB TREATMENT IN RA PATIENTS**
Genovese, M. C., Breedveld, F. C., Emery, P., Cohen, S. B., Keystone, E., Matteson, E., Baptiste, Y., Burke, L., Reiss, W., Sweetser, M., Shaw, T.
OXFORD UNIV PRESS.2009: I90-I91
 - **GOLIMUMAB SIGNIFICANTLY IMPROVES SELF-REPORTED PRODUCTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS**
Wordsworth, P., Buchanan, J., Fleischmann, R., Genovese, M., Kay, J., Hsia, E., Doyle, M., Rahman, M., Han, C., Parasuraman, S.
OXFORD UNIV PRESS.2009: I83
 - **EVALUATION OF JOINT DAMAGE IN RA PATIENTS TREATED WITH RITUXIMAB: COMPARISON OF GENANT- AND VAN DER HELJDE-MODIFIED SHARP RADIOGRAPHIC SCORING**

- Genovese, M., Peterfy, C., Emery, P., Keystone, E., Tak, P., Cohen, S. B., DiCarlo, J., Hagerty, D., Cravets, M., Shaw, T.
OXFORD UNIV PRESS.2009: I65
- **GOLIMUMAB SIGNIFICANTLY IMPROVES PHYSICAL FUNCTION, HEALTH-RELATED QUALITY OF LIFE, AND FATIGUE IN RA (GO-FORWARD STUDY)**
Rubbert, A., Genovese, M. C., Keystone, E., Hsia, E. C., Buchanan, J., Klareskog, L., Murphy, F., Wu, Z., Parasuraman, S., Rahman, M. U.
OXFORD UNIV PRESS.2009: I84
 - **IN PATIENTS WITH EARLY RA WHO HAD ACHIEVED A NORMAL CRP, ADALIMUMAB INHIBITED RADIOGRAPHIC PROGRESSION MORE EFFECTIVELY THAN METHOTREXATE** *Annual Meeting of the British-Society-of-Rheumatology*
Emery, P., Genovese, M., Van Vollenhoven, R. F., Sasso, E. H.
OXFORD UNIV PRESS.2009: I85–I85
 - **Efficacy of a p38 mitogen activated protein kinase inhibitor in mitigating an established inflammatory reaction to polyethylene particles in vivo** *JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A*
Ma, T., Ren, P., Larsen, D. M., Suenaga, E., Zilber, S., Genovese, M., Smith, R. L., Goodman, S. B.
2009; 89A (1): 117-123
 - **RAPID AND SIGNIFICANT REDUCTION IN DISEASE ACTIVITY WITH TOCILIZUMAB IN COMBINATION WITH SIX DIFFERENT DMARDS IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE RESPONSE TO DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS: THE TOWARD STUDY** *Annual Meeting of the British-Society-of-Rheumatology*
Gomez-Reino, J. J., Nasonov, E. L., McKay, J. D., Mysler, E. F., da Silva, N., Alecock, E., Woodworth, T., Genovese, M. C.
OXFORD UNIV PRESS.2009: I89–I89
 - **RAPID AND SIGNIFICANT REDUCTION OF DAS28 FOLLOWING TOCILIZUMAB TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS INADEQUATELY RESPONDING TO DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS** *Annual Meeting of the British-Society-of-Rheumatology*
Smolen, J. S., Mysler, E. F., Rubbert-Roth, A., Gomez-Reino, J., Alten, R., Law, A., Woodworth, T., Genovese, M.
OXFORD UNIV PRESS.2009: I91–I91
 - **Efficacy and safety of up to 10 years of etanercept therapy in North American patients with early and long-standing rheumatoid arthritis**
Weinblatt, M., Bathon, J., Kremer, J., Genovese, M.
MOSBY-ELSEVIER.2009: AB56
 - **Inhibition of p38: Has the Fat Lady Sung** *ARTHRITIS AND RHEUMATISM*
Genovese, M. C.
2009; 60 (2): 317-320
 - **Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies** *ANNALS OF THE RHEUMATIC DISEASES*
Keystone, E., Emery, P., Peterfy, C. G., Tak, P. P., Cohen, S., Genovese, M. C., Dougados, M., Burmester, G. R., Greenwald, M., Kvien, T. K., Williams, S., Hagerty, D., Cravets, et al
2009; 68 (2): 216-221
 - **Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis** *ARTHRITIS RESEARCH & THERAPY*
Hueber, W., Tomooka, B. H., Batliwalla, F., Li, W., Monach, P. A., Tibshirani, R. J., Van Vollenhoven, R. F., Lampa, J., Saito, K., Tanaka, Y., Genovese, M. C., Klareskog, L., Gregersen, et al
2009; 11 (3)
 - **Interleukin-6 Receptor Inhibition With Tocilizumab Reduces Disease Activity in Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Antirheumatic Drugs The Tocilizumab in Combination With Traditional Disease-Modifying Antirheumatic Drug Therapy Study** *ARTHRITIS AND RHEUMATISM*
Genovese, M. C., McKay, J. D., Nasonov, E. L., Mysler, E. F., da Silva, N. A., Alecock, E., Woodworth, T., Gomez-Rein, J. J.
2008; 58 (10): 2968-2980
 - **Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis - A phase I/II randomized, blinded, placebo-controlled, dose-ranging study** *ARTHRITIS AND RHEUMATISM*
Genovese, M. C., Kaine, J. L., Lowenstein, M. B., Del Giudice, J., Baldassare, A., Schechtman, J., Fudman, E., Kohen, M., Gujrathi, S., Trapp, R. G., Sweiss, N. J., Spaniolo, G., Dummer, et al
2008; 58 (9): 2652-2661

- **Low immunogenic potential of tocilizumab in patients with rheumatoid arthritis: Analysis of four phase 3 clinical trials**
Ramos-Remus, C., Genovese, M. C., Harre, R. A., Woodworth, T., Alecock, E.
WILEY-LISS.2008: S534
- **Concomitant use of statins in tocilizumab-treated patients with rheumatoid arthritis with elevated low density lipoprotein cholesterol: Analysis of five phase 3 clinical trials**
Genovese, M. C., Smolen, J. S., Emery, P., Jones, G., Lee, J. S., Alecock, E., Kremer, J. M.
WILEY-LISS.2008: S785–S786
- **Tocilizumab treatment results in rapid improvements in the signs and symptoms of moderate-to-severe rheumatoid arthritis in four patient Populations with different prior therapy exposure**
Smolen, J. S., Churchill, M., Rizzo, W., Ridley, D., Law, A., Bahrt, K., Genovese, M. C.
WILEY-LISS.2008: S532–S533
- **Phenotypic and functional features of th-17 cells in psoriasis and psoriatic arthritis**
Raychaudhuri, S. P., Raychaudhuri, S. K., Genovese, M. C.
WILEY-LISS.2008: S352
- **Lipid and inflammatory biomarker profiles in patients receiving tocilizumab for rheumatoid arthritis: Analysis of five phase 3 clinical trials**
Genovese, M. C., Smolen, J. S., Emery, P., Jones, G., Lee, J. S., Alecock, E., Kremer, J. M.
WILEY-LISS.2008: S531–S532
- **Adalimumab inhibited radiographic progression more effectively than methotrexate in early RA patients who had achieved a normal c-reactive protein concentration**
Emery, P., Genovese, M., van Vollenhoven, R., Ozol-Godfrey, A., Sasso, E. H.
WILEY-LISS.2008: S536
- **Golimumab administered subcutaneously every 4 wks in patients with active rheumatoid arthritis despite methotrexate: Wk 24 results of the randomized, double-blind, placebo-controlled, GO-FORWARD study** *72nd Annual Scientific Meeting of the American-College-of-Rheumatology/43rd Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals*
Keystone, E., Genovese, M. C., Klareskog, L., Hsia, E. C., Livingston, J., Wiekowski, M., Hall, S. T., Miranda, P., Pazdur, J., Bae, S. C., Palmer, W., Wu, Z., Rahman, et al
WILEY-BLACKWELL.2008: S618–S619
- **IL-6 receptor inhibition with tocilizumab reduces disease activity in patients with rheumatoid arthritis with inadequate response to a range of DMARDs: The TOWARD study** *16th Winter Workshop of the Canadian-Rheumatology-Association*
Genovese, M., Brown, J. P., McKay, J., Nasonov, E., Mysler, E., da Silva, N., Alecock, E., Gomez-Reino, J.
J RHEUMATOL PUBL CO.2008: 1187–87
- **Targeted inhibition of IL-6 signaling with tocilizumab improves quality of life and function in patients with rheumatoid arthritis with inadequate response to a range of DMARDs** *16th Winter Workshop of the Canadian-Rheumatology-Association*
Gomez-Reino, J. J., Nair, B., FAIRFAX, M. J., Pavelka, K., Alecock, E., Woodworth, T., Genovese, M.
J RHEUMATOL PUBL CO.2008: 1216–16
- **Inhibition of radiographic progression with rituximab is not dependent on clinical efficacy: Results from a study in rheumatoid arthritis patients with an inadequate response to one or more TNF inhibitors (reflex)** *Annual Meeting of the British-Society-Rheumatology/Spring Meeting of British Health Professional in Rheumatology*
Emery, P., Keystone, E., Peterfy, C. G., Tak, P., Cohen, S. B., Genovese, M. C., Williams, S., Hagerty, D., Cravets, M. W., Shaw, T. M.
OXFORD UNIV PRESS.2008: II50–II50
- **Improved remission rates with the IL-6R inhibitor tocilizumab (TCZ) in patients with active rheumatoid arthritis despite DMARD therapy: The toward study**
Genovese, M. C., Mckay, J. D., Nasonov, E. L., Mysler, E. F., da Silva, N. A., Alecock, E., Woodworth, T., Loughton, J., Eves, D., Gomez-Reino, J. J.
OXFORD UNIV PRESS.2008: II50
- **Repeat treatment with rituximab in active RA patients: Long-term efficacy in patients with one versus two or more prior TNF inhibitors**
Emery, P., Kremer, J. M., Tony, H. P., Genovese, M. C., Tak, P., Luggen, M., Bombardieri, S., Hesse, E., Safa-Leathers, S.
OXFORD UNIV PRESS.2008: II38
- **Safety of tnf inhibitors and non-biologic DMARDs in rheumatoid arthritis patients previously treated with rituximab**
Emery, P., Genovese, M. C., Breedveld, F., Moreland, L., Keystone, E., Matteson, E. L., Baptiste, Y., Reiss, W., Sweetser, M., Shaw, T.

OXFORD UNIV PRESS.2008: II48-II49

- **Radiographic progression and clinical status are differentially related for adalimumab plus methotrexate (MTX) vs. monotherapy with adalimumab or MTX: Subanalysis of premier** *Annual Meeting of the British-Society-Rheumatology/Spring Meeting of British Health Professional in Rheumatology*
Emery, P., Genovese, M., van Vollenhoven, R., Patra, K., Sasso, E.
OXFORD UNIV PRESS.2008: III15-III16
- **Quality of life and functional improvements with the IL-6 receptor inhibitor tocilizumab in patients with active rheumatoid arthritis despite DMARD therapy: The toward study** *Annual Meeting of the British-Society-Rheumatology/Spring Meeting of British Health Professional in Rheumatology*
Gomez-Reino, J. J., FAIRFAX, M. J., Pavelka, K., Alecock, E., Woodworth, T., Laughton, J., Eves, D., Genovese, M. C.
OXFORD UNIV PRESS.2008: II49-II49
- **Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy** *ANNALS OF THE RHEUMATIC DISEASES*
Genovese, M. C., Schiff, M., Luggen, M., Becker, J., Aranda, R., Teng, J., Li, T., Schmidely, N., Le Bars, M., Dougados, M.
2008; 67 (4): 547-554
- **Efficacy and safety of up to 10 years of etanercept therapy in North American patients with early and long-standing rheumatoid arthritis**
Weinblatt, M., Genovese, M., Moreland, L., Bathon, J.
MOSBY-ELSEVIER.2008: AB47
- **Safety of TNF inhibitors (TNF-is) and non-biologic DMARDs in rheumatoid arthritis (RA) patients (pts) previously treated with Rituximab (RTX)**
Genovese, M., van Vollenhoven, R., Breedveld, F., Emery, P., Moreland, L., Keystone, E., Matteson, E., Baptiste, Y., Burke, L., Reiss, W., Sweetser, M., Shaw, T.
INFORMA HEALTHCARE.2008: 44-44
- **Longitudinal Evaluation of the Occurrence of MRI-Detectable Bone Marrow Edema in Osteoarthritis of the Knee** *ACTA RADIOLOGICA*
Brem, M. H., Schlechtweg, P. M., Bhagwat, J., Genovese, M., Dillingham, M. F., Yoshioka, H., Lang, P.
2008; 49 (9): 1031-1037
- **Reduced B lymphocyte and immunoglobulin levels after atacept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial.** *Arthritis and rheumatism*
Dall'Era, M., Chakravarty, E., Wallace, D., Genovese, M., Weisman, M., Kavanaugh, A., Kalunian, K., Dhar, P., Vincent, E., Pena-Rossi, C., Wofsy, D.
2007; 56 (12): 4142-4150
- **Reduced B lymphocyte and immunoglobulin levels after atacept treatment in patients with systemic lupus erythematosus** *ARTHRITIS AND RHEUMATISM*
Dall'Era, M., Chakravarty, E., Wallace, D., Genovese, M., Weisman, M., Kavanaugh, A., Kalunian, K., Dhar, P., Vincent, E., Pena-Rossi, C., Wofsy, D., Serono, M.
2007; 56 (12): 4142-4150
- **IL-6 receptor inhibition with tocilizumab reduces disease activity in patients with rheumatoid arthritis with inadequate response to a range of DMARDs: The TOWARD study** *71st Annual Scientific Meeting of the American-College-of-Rheumatology/42nd Association-of-Rheumatology-Health-Professionals*
Genovese, M., McKay, J., Nasonov, E., Myster, E., da Silva, N., Alecock, E., Woodworth, T., Gomez-Reino, J.
WILEY-LISS.2007: 4309-10
- **Targeted inhibition of IL-6 signalling with tocilizumab improves quality of life and function in patients with rheumatoid arthritis with inadequate response to a range of DMARDs** *71st Annual Scientific Meeting of the American-College-of-Rheumatology/42nd Association-of-Rheumatology-Health-Professionals*
Gomez-Reino, J. J., FAIRFAX, M. J., Pavelka, K., Alecock, E., Woodworth, T., Genovese, M.
WILEY-LISS.2007: 4234-34
- **Efficacy results from pivotal clinical trials with abatacept** *CLINICAL AND EXPERIMENTAL RHEUMATOLOGY*
Rozelle, A. L., Genovese, M. C.
2007; 25 (5): S30-S34
- **Impact of a positive youth development program in urban after-school settings on the prevention of adolescent substance use** *JOURNAL OF ADOLESCENT HEALTH*
Tebes, J. K., Feinn, R., Vanderploeg, J. J., Chinman, M. J., Shepard, J., Brabham, T., Genovese, M., Connell, C.
2007; 41 (3): 239-247
- **Safety of TNF inhibitors in rheumatoid arthritis patients previously treated with rituximab** *15th Winter Meeting of the Canadian-Rheumatology-Association*
Breedveld, F. C., Khraishi, M. M., Genovese, M., Emery, P., Moreland, L. W., Keystone, E., Matteson, E. L., Burke, L., Agarwal, S., Kim, D., Cooper, S.

J RHEUMATOL PUBL CO.2007: 1602-

- **A pilot trial of rituximab in the treatment of patients with dermatomyositis** *ARCHIVES OF DERMATOLOGY*
Chung, L., Genovese, M. C., Fiorentino, D. F.
2007; 143 (6): 763-767
- **Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines** *ANNALS OF THE RHEUMATIC DISEASES*
Hueber, W., Tomooka, B. H., Zhao, X., Kidd, B. A., Drijfhout, J. W., Fries, J. F., van Venrooij, W. J., Metzger, A. L., Genovese, M. C., Robinson, W. H.
2007; 66 (6): 712-719
- **A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands** *JOURNAL OF RHEUMATOLOGY*
Magnano, M. D., Chakravarty, E. F., Broudy, C., Chung, L., Kelman, A., Hillygus, J., Genovese, M. C.
2007; 34 (6): 1323-1327
- **Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy** *JOURNAL OF RHEUMATOLOGY*
Genovese, M. C., Mease, P. J., Thomson, G. T., Kivitz, A. J., Perdok, R. J., Weinberg, M. A., Medich, J., Sasso, E. H.
2007; 34 (5): 1040-1050
- **Sustained efficacy along with improvements in disease activity score 28 (DAS 28) and patient (Pt)-reported outcomes (PROs) with abatacept (Aba) in rheumatoid arthritis (RA) pts with an inadequate response to anti-tumor necrosis factor (TNF) therapy: The long-term extension (LTE) of the attain trial** *Annual Meeting of the British-Society-of-Rheumatology*
Dougados, M., Schiff, M., Luggen, M., Becker, J. C., Aranda, R., Li, T., McCann, T., Schmidely, N., LeBars, M., Sibia, J., Genovese, M. C.
OXFORD UNIV PRESS.2007: 199-199
- **Signal transduction blockade with imatinib mesylate prevents and treats autoimmune arthritis**
Paniagua, R., Sharpe, O., Ho, P., Chan, S., Chang, A., Tomooka, B., Lee, D., Genovese, M., Utz, P., Steinman, L., Robinson, W.
AMER ASSOC IMMUNOLOGISTS.2007
- **Safety and efficacy of up to 9 years of etanercept therapy in North American patients with rheumatoid arthritis**
Weinblatt, M., Genovese, M., Moreland, L., Bathon, J.
MOSBY-ELSEVIER.2007: AB183
- **Trial of atacicept in patients with systemic lupus erythematosus (SLE).**
Dall'Era, M., Chakravarty, E., Genovese, M., Wallace, D., Kavanaugh, A., Kalunian, K., Dhar, P., Pena-Rossi, C., Wofsy, D., Sero Zymogenetics Atacicept S
WILEY-LISS.2006: 4042-43
- **Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis** *JOURNAL OF CLINICAL INVESTIGATION*
Paniagua, R. T., Sharpe, O., Ho, P. P., Chan, S. M., Chang, A., Higgins, J. P., Tomooka, B. H., Thomas, F. M., Song, J. J., Goodman, S. B., Lee, D. M., Genovese, M. C., Utz, et al
2006; 116 (10): 2633-2642
- **Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis.** *70th Annual Scientific Meeting of the American-College-of-Rheumatology/41st Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals*
Robinson, W. H., Paniagua, R. T., Ho, P. P., Chan, S. M., Sharpe, O., Utz, P. J., Genovese, M. C.
WILEY-BLACKWELL.2006: S356-S357
- **Inhibition of joint structural damage with rituximab is not dependant on clinical response in rheumatoid arthritis patients with an inadequate response to one or more TNF inhibitors (REFLEX study).**
Keystone, E., Emery, P., Peterfy, C. G., Tak, P. P., Cohen, S. B., Genovese, M. C., Williams, S., Totoritis, M. C., Cravets, M. W., Shaw, T.
WILEY-LISS.2006: S542-S543
- **Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks** *ARTHRITIS AND RHEUMATISM*
Cohen, S. B., Emery, P., Greenwald, M. W., Dougados, M., Furie, R. A., Genovese, M. C., Keystone, E. C., Loveless, J. E., Burmester, G., Cravets, M. W., Hesse, E. W., Shaw, T., Totoritis, et al
2006; 54 (9): 2793-2806
- **A pilot study of TNF inhibition in Erosive/Inflammatory osteoarthritis of the hands.** *70th Annual Scientific Meeting of the American-College-of-Rheumatology/41st Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals*
Magnano, M. D., Chakravarty, E. F., Broudy, C., Chung, L., Kelman, A., Hillygus, J. J., Genovese, M. C.

WILEY-BLACKWELL.2006: S674–S674

- **Sustained efficacy and safety through 2 years in patients with rheumatoid arthritis (RA) in the long-term extension of the ATTAIn trial.** *70th Annual Scientific Meeting of the American-College-of-Rheumatology/41st Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals*
Genovese, M. C., Schiff, M., Luggen, M., Becker, J., Aranda, R., McCann, T., Schmidely, N., Le Bars, M., Dougados, M.
WILEY-BLACKWELL.2006: S244–S244
- **Safety of TNF inhibitors in rheumatoid arthritis patients previously treated with rituximab**
Breedveld, F. C., Van Vollenhoven, R. F., Genovese, M., Emery, P., Moreland, L. W., Keystone, E., Matteson, E. L., Burke, L., Agarwal, S., Kim, D., Cooper, S.
TAYLOR & FRANCIS AS.2006: 11–11
- **Safety of TNF inhibitors in rheumatoid arthritis patients previously treated with rituximab** *Annual European Congress of Rheumatology (EULAR 2006)*
Breedveld, F. C., Genovese, M., Emery, P., Moreland, L. W., Keystone, E., Matteson, E. L., Burke, L., Agarwal, S., Kim, D., Cooper, S.
BMJ PUBLISHING GROUP.2006: 178–179
- **Effect of etanercept on fatigue in patients with recent or established rheumatoid arthritis** *ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH*
Moreland, L. W., Genovese, M. C., Sato, R., Singh, A.
2006; 55 (2): 287-293
- **Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients - Patient-reported outcomes from multiple controlled and open-label extension studies** *DRUGS & AGING*
Schiff, M. H., Yu, E. B., Weinblatt, M. E., Moreland, L. W., Genovese, M. C., White, B., Singh, A., Chon, Y., Woolley, J. M.
2006; 23 (2): 167-178
- **A randomized, blinded, parallel group, placebo controlled pilot study evaluating the effect of PVAC treatment in patients with diffuse systemic sclerosis** *JOURNAL OF RHEUMATOLOGY*
Genovese, M. C., Chakravarty, E. F., Boyle, D. L., Tutuncu, Z., Thorburn, C. M., Halilhodzic, M., KROLL, S., Baughman, J., Stewart, S., Kavanaugh, A.
2005; 32 (12): 2345-2350
- **Rituximab in the treatment of patients with dermatomyositis: 12 week interim analysis of a pilot trial.**
Chung, L., Genovese, M. C., Fiorentino, D.
WILEY-LISS.2005: 4088
- **Computer-assisted pattern recognition of autoantibody results** *CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY*
Binder, S. R., Genovese, M. C., Merrill, J. T., Morris, R. I., Metzger, A. L.
2005; 12 (12): 1353-1357
- **Management of co-morbidities and general medical conditions in patients with rheumatoid arthritis.** *Current rheumatology reports*
Magnano, M. D., Genovese, M. C.
2005; 7 (5): 407-415
- **Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition** *NEW ENGLAND JOURNAL OF MEDICINE*
Genovese, M. C., Becker, J., Schiff, M., Luggen, M., Sherrer, Y., Kremer, J., Birbara, C., Box, J., Natarajan, K., Nuamah, I., Li, T., Aranda, R., Hagerty, et al
2005; 353 (11): 1114-1123
- **Antigen microarray profiling of autoantibodies in rheumatoid arthritis** *ARTHRITIS AND RHEUMATISM*
Hueber, W., Kidd, B. A., Tomooka, B. H., Lee, B. J., Bruce, B., Fries, J. F., Sonderstrup, G., Monach, P., Drijfhout, J. W., van Venrooij, W. J., Utz, P. J., Genovese, M. C., Robinson, et al
2005; 52 (9): 2645-2655
- **Differential responsiveness to belimumab (BmAb) in combination with standard of care therapy in RF plus , TNF alpha-inhibitor and methotrexate partial responder subgroups of subjects with moderate-severe rheumatoid arthritis**
Genovese, M., Filipowicz-Sosnowska, A., Merrill, J., Wasko, M., Dilorio, E., Stevenson, J., Lisse, J., Zhong, J., Hall, L., Bieber, F., Zilberstein, M., LBRA01 Study Grp
WILEY-BLACKWELL.2005: S738
- **Fibrinogen-induced arthritis in mice as a novel model for rheumatoid arthritis.**
Robinson, W. H., Tomooka, B., Genovese, M. C., Ho, P. P.
WILEY-BLACKWELL.2005: S157
- **Integrated serum proteome analysis of autoantibodies and cytokines delineates distinct biosignatures in subsets of patients with early RA.**

- Hueber, W., Tomooka, B., Bruce, B., Monach, P., Fries, J. F., van Venrooij, W., Zatarain, E., Genovese, M. C., Robinson, W. H.
WILEY-BLACKWELL.2005: S276–S277
- **The relationship of radiographic progression to clinical response in patients with early RA treated with adalimumab (HUMIRA (R)) plus MTX or MTX alone.**
Genovese, M. C., Kavanaugh, A. F., Cohen, S. B., Emery, P., Sasso, E. H., Spencer-Green, G. T.
WILEY-BLACKWELL.2005: S451
 - **Efficacy and safety of over 8 years of etanercept (Enbrel (R)) therapy in North American patients with early and long-standing rheumatoid arthritis.**
Weinblatt, M. E., Genovese, M. C., Moreland, L. W., Bathon, J. M., Kremer, J. M., Fleischmann, R. M., Schiff, M. H., Xia, H. A., Peloso, P., White, B.
WILEY-BLACKWELL.2005: S541
 - **Selective co-stimulation modulation with abatacept leads to improvements in ACR responses in patients with an inadequate response to etanercept, infliximab or both: The ATTAIn trial.** *69th Annual Scientific Meeting of the American-College-of-Rheumatology/40th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals*
Dougados, M., Kavanaugh, A., Espinoza, L., Sibilia, J., Aranda, R., Becker, J. C., White, A., Genovese, M., Schiff, M., Luggen, M.
WILEY-BLACKWELL.2005: S137–S138
 - **The impact of disease duration on improvements in ACR responses and remission following abatacept treatment in patients with an inadequate response 2 to anti-TNF therapy in the ATTAIn trial.** *69th Annual Scientific Meeting of the American-College-of-Rheumatology/40th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals*
Genovese, M., Luggen, M., Kremer, J., Sany, J., Aranda, R., Becker, J. C., White, A., Schiff, M., Dougados, M.
WILEY-BLACKWELL.2005: S137–S137
 - **Efficacy of abatacept following wash-out of anti-TNF therapy in rheumatoid arthritis patients in the ATTAIn (Abatacept Trial in Treatment of Anti-TNF INadequate Responders) trial: Current versus prior discontinuation.** *69th Annual Scientific Meeting of the American-College-of-Rheumatology/40th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals*
Genovese, M., Schiff, M., Luggen, M., Aranda, R., Becker, J. C., White, A., Dougados, M.
WILEY-BLACKWELL.2005: S560–S561
 - **Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis** *JOURNAL OF RHEUMATOLOGY*
Genovese, M. C., Bathon, J. M., Fleischmann, R. M., Moreland, L. W., Martin, R. W., Whitmore, J. B., Tsuji, W. H., Leff, J. A.
2005; 32 (7): 1232-1242
 - **Abatacept leads to significant improvements in all American college of rheumatology core components in patients with an inadequate response to anti-TNF therapy in the attain trial** *Annual European Congress of Rheumatology*
Schiff, M., Dougados, M., Luggen, M., Espinoza, L., Nuamah, I., Aranda, R., Becker, J., Genovese, M.
BMJ PUBLISHING GROUP.2005: 435–436
 - **Beneficial effects of the selective CO-stimulation modulator abatacept on biomarkers of rheumatoid arthritis immunopathology in patients with an inadequate response to methotrexate or TNF-inhibitor treatment** *Annual European Congress of Rheumatology*
Emery, R., Westhovens, R., LEON, G., Nuamah, I., Ge, Z., Aranda, R., Becker, J., Genovese, M., Dougados, M.
BMJ PUBLISHING GROUP.2005: 432–433
 - **Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus** *71st Annual Meeting of the Central-Association-of-Obstetricians-and-Gynecologists*
Chakravarty, E. F., Colon, I., Langen, E. S., Nix, D. A., El-Sayed, Y. Y., Genovese, M. C., Druzin, M. L.
MOSBY-ELSEVIER.2005: 1897–1904
 - **Biologic therapies in clinical development for the treatment of rheumatoid arthritis** *JCR-JOURNAL OF CLINICAL RHEUMATOLOGY*
Genovese, M. C.
2005; 11 (3): S45-S54
 - **Temporal effects of a COX-2-selective NSAID on bone ingrowth.** *Journal of biomedical materials research. Part A*
Goodman, S. B., Ma, T., Mitsunaga, L., Miyanishi, K., Genovese, M. C., Smith, R. L.
2005; 72 (3): 279-287
 - **Temporal effects of a COX-2-selective NSAID on bone ingrowth** *JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A*
Goodman, S. B., Ma, T., Mitsunaga, L., Miyanishi, K., Genovese, M. C., Smith, R. L.
2005; 72A (3): 279-287

- **Pharmacologic modulation of periprosthetic osteolysis** *CLINICAL ORTHOPAEDICS AND RELATED RESEARCH*
Goodman, S. B., Trindade, M., Ma, T., Genovese, M., Smith, R. L.
2005; 39-45
- **A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis** *ANNALS OF THE RHEUMATIC DISEASES*
van Holten, J., Pavelka, K., Vencovsky, J., Stahl, H., Rozman, B., Genovese, M., Kivitz, A. J., Alvaro, J., Nuki, G., Furst, D. E., Herrero-Beaumont, G., McInnes, I. B., Musikic, et al
2005; 64 (1): 64-69
- **Fibrinogen-induced arthritis in mice as a novel model for rheumatoid arthritis.** *5th Annual Meeting of the Federation-of-Clinical-Immunology-Societies*
Ho, P. P., Tomooka, B. H., Higgins, J. P., Lee, L. Y., Genovese, M., Robinson, W. H.
ACADEMIC PRESS INC ELSEVIER SCIENCE.2005: S32-S32
- **Efficacy and safety of abatacept (CTLA41g), a selective co-stimulation modulator, in rheumatoid arthritis patients not responding adequately to anti-TNF-alpha therapy: Results of the phase III ATTAIN (Abatacept trial in treatment of Anti-TNF INadequate responders)** *68th Annual Scientific Meeting of the American-College-of-Rheumatology/39th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals*
Genovese, M., Luggen, M., Schiff, M., Sherrer, Y., Nuamah, I., Aranda, R., Becker, J. C., Dougados, M.
WILEY-BLACKWELL.2004: 4103-
- **Magnetic resonance imaging of articular cartilage of the knee: Comparison between fat-suppressed three-dimensional SPGR imaging, fat-suppressed FSE imaging, and fat-suppressed three-dimensional DEFT imaging, and correlation with arthroscopy** *JOURNAL OF MAGNETIC RESONANCE IMAGING*
Yoshioka, H., Stevens, K., Hargreaves, B. A., Steines, D., Genovese, M., Dillingham, M. F., Winalski, C. S., Lang, P.
2004; 20 (5): 857-864
- **Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus.** *Arthritis and rheumatism*
Petri, M. A., Mease, P. J., Merrill, J. T., Lahita, R. G., Iannini, M. J., Yocum, D. E., Ginzler, E. M., Katz, R. S., Gluck, O. S., Genovese, M. C., van Vollenhoven, R., Kalunian, K. C., Manzi, et al
2004; 50 (9): 2858-2868
- **Demyelination and inhibition of tumor necrosis factor (TNF)** *CLINICAL AND EXPERIMENTAL RHEUMATOLOGY*
Magnano, M. D., Robinson, W. H., Genovese, M. C.
2004; 22 (5): S134-S140
- **Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus - Results of a multicenter randomized, double-blind, placebo-controlled trial** *Annual Meeting of the British-Society-for-Rheumatology*
Petri, M. A., Mease, P. J., Merrill, J. T., Lahita, R. G., Iannini, M. J., Yocum, D. E., GINZLER, E. M., Katz, R. S., Gluck, O. S., Genovese, M. C., van Vollenhoven, R., Kalunian, K. C., Manzi, et al
WILEY-LISS.2004: 2858-68
- **Arthritis antigen microarray analysis reveals associations of distinct autoantibody profiles with markers of disease activity and severity in RA.** *68th Annual Scientific Meeting of the American-College-of-Rheumatology/39th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals*
Hueber, W., Kidd, B., Lee, B. J., Genovese, M., Bruce, B., Fries, J., van Venrooij, W., Robinson, W. H.
WILEY-BLACKWELL.2004: S651-S651
- **A randomized, blinded, parallel group, placebo-controlled, pilot study evaluating the effect of Pvac treatment in patients with diffuse systemic sclerosis** *68th Annual Scientific Meeting of the American-College-of-Rheumatology/39th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals*
Genovese, M. C., Boyle, D., Chakravarty, E., Tutuncu, Z., Thorburn, C., Halilhodzic, M., KROLL, S., Stewart, S., Baughman, J., Kavanaugh, A.
WILEY-BLACKWELL.2004: S636-S636
- **Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: Open-label extension of a randomized, double-blind, placebo controlled trial** *JOURNAL OF RHEUMATOLOGY*
Kremer, J., Genovese, M., Cannon, G. W., Caldwell, J., Cush, J., Furst, D. E., Luggen, M., Keystone, E. D., Bathon, J., Kavanaugh, A., Ruderman, E., Coleman, P., Curtis, et al
2004; 31 (8): 1521-1531
- **The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis** *JOURNAL OF RHEUMATOLOGY*
Hansen, K. E., Hildebrand, J. P., Genovese, M. C., Cush, J. J., Patel, S., Cooley, D. A., Cohen, S. B., Gangnon, R. E., Schiff, M. H.
2004; 31 (6): 1098-1102

- **Associations between rheumatoid arthritis and malignancy** *RHEUMATIC DISEASE CLINICS OF NORTH AMERICA*
Chakravarty, E. F., Genovese, M. C.
2004; 30 (2): 271-?
- **Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate** *ARTHRITIS AND RHEUMATISM*
Genovese, M. C., Cohen, S., Moreland, L., Lium, D., Robbins, S., Newmark, R., Bekker, P.
2004; 50 (5): 1412-1419
- **Treatment of rheumatoid arthritis with etanercept** *RHEUMATIC DISEASE CLINICS OF NORTH AMERICA*
Genovese, M. C., Kremer, J. M.
2004; 30 (2): 311-?
- **The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis** *ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH*
Hansen, K. E., Cush, J., Singhal, A., Cooley, D. A., Cohen, S., Patel, S. R., Genovese, M., Sundaramurthy, S., Schiff, M.
2004; 51 (2): 228-232
- **Unlocking the "PAD" lock on rheumatoid arthritis** *ANNALS OF THE RHEUMATIC DISEASES*
Utz, P. J., Genovese, M. C., Robinson, W. H.
2004; 63 (4): 330-332
- **Articular cartilage of knee: Normal patterns at MR imaging that mimic disease in healthy subjects and patients with osteoarthritis** *RADIOLOGY*
Yoshioka, H., Stevens, K., Genovese, M., Dillingham, M. F., Lang, P.
2004; 231 (1): 31-38
- **A randomized, controlled trial of interferon-beta-1a (Avonex(R)) in patients with rheumatoid arthritis: a pilot study [ISRCTN03626626].** *Arthritis research & therapy*
Genovese, M. C., Chakravarty, E. F., Krishnan, E., Moreland, L. W.
2004; 6 (1): R73-R77
- **A randomized, controlled trial of interferon-beta-1a (Avonex (R)) in patients with rheumatoid arthritis: a pilot study [ISRCTN03626626]** *ARTHRITIS RESEARCH & THERAPY*
Genovese, M. C., Chakravarty, E. F., Krishnan, E., Moreland, L. W.
2004; 6 (1): R73-R77
- **Interleukin 1 receptor antagonist inhibits localized bone formation in vivo** *JOURNAL OF RHEUMATOLOGY*
Ma, T., Miyanishi, K., Trindade, M. C., Genovese, M., Regula, D., Smith, R. L., Goodman, S. B.
2003; 30 (12): 2547-2552
- **COX-2 selective inhibitors and bone** *INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY*
Goodman, S. B., Ma, T., Genovese, M., Smith, R. L.
2003; 16 (3): 201-205
- **The Early Rheumatoid Arthritis (ERA) Trial comparing the efficacy and safety of etanercept and methotrexate** *CLINICAL AND EXPERIMENTAL RHEUMATOLOGY*
Bathon, J. M., Genovese, M. C.
2003; 21 (5): S195-S197
- **Synovial proteome microarrays identify deiminated proteins as targets of the autoantibody response in Rheumatoid Arthritis** *67th Annual Scientific Meeting of the American-College-of-Rheumatology/38th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals*
Hueber, W., Lee, B. J., Genovese, M. C., Bruce, B., van Venrooij, W. J., Smolen, J. S., Steinman, L., Utz, P. J., Robinson, W. H.
WILEY-BLACKWELL.2003: S429-S429
- **Imaging of the articular cartilage in osteoarthritis of the knee joint: 3D spatial-spectral spoiled gradient-echo vs. fat-suppressed 3D spoiled gradient-echo MR imaging** *JOURNAL OF MAGNETIC RESONANCE IMAGING*
Yoshioka, H., Alley, M., Steines, D., Stevens, K., Rubesova, E., Genovese, M., Dillingham, M. F., Lang, P.
2003; 18 (1): 66-71
- **CTLA4IG (BMS-188667) in a phase IIB, multi-center, randomized, double-blind, placebo controlled study in rheumatoid arthritis patients receiving etanercept: Association between clinical response and key biomarkers** *Annual European Congress of Rheumatology*

- Schiff, M., Genovese, M., Nuamah, I., Becker, J., Weinblatt, M.
BMJ PUBLISHING GROUP.2003: 178-178
- **Modulation of bone ingrowth and tissue differentiation by local infusion of interleukin-10 in the presence of ultra-high molecular weight polyethylene (UHMWPE) wear particles.** *Journal of biomedical materials research. Part A*
Goodman, S., Trindade, M., Ma, T., Lee, M., Wang, N., Ikenou, T., Matsuura, I., Miyanishi, K., Fox, N., Regula, D., Genovese, M., Klein, J., Bloch, et al
2003; 65 (1): 43-50
 - **Modulation of bone ingrowth and tissue differentiation by local infusion of interleukin-10 in the presence of ultra-high molecular weight polyethylene (UHMWPE) wear particles** *JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A*
Goodman, S., Trindade, M., Ma, T., Lee, M., Wang, N., Ikenou, T., Matsuura, I., Miyanishi, K., Fox, N., Regula, D., Genovese, M., Klein, J., Bloch, et al
2003; 65A (1): 43-50
 - **Allele and antigen-specific treatment of rheumatoid arthritis: A double blind, placebo controlled phase 1 trial** *JOURNAL OF RHEUMATOLOGY*
Kavanaugh, A., Genovese, M., Baughman, J., Kivitz, A., Bulpitt, K., Olsen, N., Weisman, M., Matteson, E., Furst, D., van Vollenhoven, R., Anderson, J., Cohen, S., Wei, et al
2003; 30 (3): 449-454
 - **Rheumatic syndromes associated with malignancy** *CURRENT OPINION IN RHEUMATOLOGY*
Chakravarty, E., Genovese, M. C.
2003; 15 (1): 35-43
 - **Multiplex autoantibody profiling using 'synovial proteome' microarrays identifies citrulline-modified peptides as major targets of the autoimmune response in rheumatoid arthritis** *3rd World Congress of the Global-Arthritis-Research-Network (GARN)*
Hueber, W., Lee, B. J., Genovese, M., van Venrooij, W., Steinman, L., Utz, P. J., Robinson, W. H.
BIOMED CENTRAL LTD.2003: S31-S31
 - **Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate - A randomized, double-blind, placebo-controlled trial** *ANNALS OF INTERNAL MEDICINE*
Kremer, J. M., Genovese, M. C., Cannon, G. W., Caldwell, J. R., Cush, J. J., Furst, D. E., Luggen, M. E., Keystone, E., Weisman, M. H., Bensen, W. M., Kaine, J. L., Ruderman, E. M., Coleman, et al
2002; 137 (9): 726-733
 - **COX-2 selective NSAID decreases bone ingrowth in vivo** *JOURNAL OF ORTHOPAEDIC RESEARCH*
Goodman, S., Ma, T., Trindade, M., Ikenoue, T., Matsuura, I., Wong, N., Fox, N., Genovese, M., Regula, D., Smith, R. L.
2002; 20 (6): 1164-1169
 - **The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis.** *66th Annual Scientific Meeting of the American-College-of-Rheumatology/37th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals*
Hansen, K. E., Cush, J. J., Patel, S., Genovese, M. C., Schiff, M.
WILEY-BLACKWELL.2002: S538-S538
 - **Central nervous system lupus and pregnancy: 11-year experience at a single center.** *journal of maternal-fetal & neonatal medicine*
El-Sayed, Y. Y., Lu, E. J., Genovese, M. C., Lambert, R. E., Chitkara, U., Druzin, M. L.
2002; 12 (2): 99-103
 - **Etanercept versus methotrexate in patients with early rheumatoid arthritis - Two-year radiographic and clinical outcomes** *ARTHRITIS AND RHEUMATISM*
Genovese, M. C., Bathon, J. M., Martin, R. W., Fleischmann, R. M., Tesser, J. R., Schiff, M. H., Keystone, E. C., Wasko, M. C., Moreland, L. W., Weaver, A. L., Markenson, J., Cannon, G. W., Spencer-Green, et al
2002; 46 (6): 1443-1450
 - **Long-term followup of patients treated with total lymphoid irradiation for lupus nephritis** *ARTHRITIS AND RHEUMATISM*
Genovese, M. C., Uhrin, Z., Bloch, D. A., Oehlert, J., Sibley, R. K., Myers, B., Strober, S.
2002; 46 (4): 1014-1018
 - **Autoantigen microarrays for multiplex characterization of autoantibody responses** *NATURE MEDICINE*
Robinson, W. H., DiGennaro, C., Hueber, W., Haab, B. B., KAMACHI, M., Dean, E. J., Fournel, S., Fong, D., Genovese, M. C., de Vegvar, H. E., Skriner, K., Hirschberg, D. L., Morris, et al
2002; 8 (3): 295-301

- **Expression of the chemokine receptors CCR4, CCR5, and CXCR3 by human tissue-infiltrating lymphocytes** *AMERICAN JOURNAL OF PATHOLOGY*
Kunkel, E. J., Boisvert, J., Murphy, K., Vierra, M. A., Genovese, M. C., Wardlaw, A. J., Greenberg, H. B., Hodge, M. R., Wu, L. J., BUTCHER, E. C., Campbell, J. J.
2002; 160 (1): 347-355
- **Rules of chemokine receptor association with T cell polarization in vivo** *JOURNAL OF CLINICAL INVESTIGATION*
Kim, C. H., Rott, L., Kunkel, E. J., Genovese, M. C., Andrew, D. P., Wu, L. J., BUTCHER, E. C.
2001; 108 (9): 1331-1339
- **Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism - By what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?** *ARTHRITIS AND RHEUMATISM*
Robinson, W. H., Genovese, M. C., Moreland, L. W.
2001; 44 (9): 1977-1983
- **Treatment of rheumatoid arthritis with total lymphoid irradiation - Long-term survival** *ARTHRITIS AND RHEUMATISM*
Uhrin, Z., Wang, B. W., Matsuda, Y., Strober, S., Genovese, M. C.
2001; 44 (7): 1525-1528
- **Combination therapy of leflunomide (LEF) & methotrexate (MTX) is effective & well tolerated in RA patients inadequately responding to MTX alone**
Kremer, J. M., Genovese, M., Cannon, G. W., Caldwell, J. R., Cush, J. J., Bathon, J.
J RHEUMATOL PUBL CO.2001: 105-105
- **Bonzo/CXCR6 expression defines type 1-polarized T-cell subsets with extralymphoid tissue homing potential** *JOURNAL OF CLINICAL INVESTIGATION*
Kim, C. H., Kunkel, E. J., Boisvert, J., Johnston, B., Campbell, J. J., Genovese, M. C., Greenberg, H. B., BUTCHER, E. C.
2001; 107 (5): 595-601
- **Current management of rheumatoid arthritis** *HOSPITAL PRACTICE*
Genovese, M. C., Davis, J. S.
2001; 36 (2): 21-?
- **CCR7 expression and memory T cell diversity in humans** *JOURNAL OF IMMUNOLOGY*
Campbell, J. J., Murphy, K. E., Kunkel, E. J., Brightling, C. E., Soler, D., Shen, Z. M., Boisvert, J., Greenberg, H. B., Vierra, M. A., Goodman, S. B., Genovese, M. C., Wardlaw, A. J., BUTCHER, et al
2001; 166 (2): 877-884
- **A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis** *NEW ENGLAND JOURNAL OF MEDICINE*
Bathon, J. M., Martin, R. W., Fleischmann, R. M., Tesser, J. R., Schiff, M. H., Keystone, E. C., Genovese, M. C., Wasko, M. C., Moreland, L. W., Weaver, A. L., Markenson, J., Finck, B. K.
2000; 343 (22): 1586-1593
- **A novel chemokine ligand for CCR10 and CCR3 expressed by epithelial cells in mucosal tissues.** *Journal of immunology*
Pan, J., Kunkel, E. J., Gossler, U., Lazarus, N., Langdon, P., Broadwell, K., Vierra, M. A., Genovese, M. C., BUTCHER, E. C., Soler, D.
2000; 165 (6): 2943-2949
- **Cutting edge: A novel chemokine ligand for CCR10 and CCR3 expressed by epithelial cells in mucosal tissues** *JOURNAL OF IMMUNOLOGY*
Pan, J. L., Kunkel, E. J., Gossler, U., Lazarus, N., Langdon, P., Broadwell, K., Vierra, M. A., Genovese, M. C., BUTCHER, E. C., Soler, D.
2000; 165 (6): 2943-2949
- **Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestinal immune compartment: Epithelial expression of tissue-specific chemokines as an organizing principle in regional immunity** *JOURNAL OF EXPERIMENTAL MEDICINE*
Kunkel, E. J., Campbell, J. J., Haraldsen, G., Pan, J. L., Boisvert, J., Roberts, A. I., Ebert, E. C., Vierra, M. A., Goodman, S. B., Genovese, M. C., Wardlaw, A. J., Greenberg, H. B., Parker, et al
2000; 192 (5): 761-767
- **A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus** *LUPUS*
van Vollenhoven, R. F., Park, J. L., Genovese, M. C., West, J. P., McGuire, J. L.
1999; 8 (3): 181-187
- **Joint and soft-tissue injection - A useful adjuvant to systemic and local treatment** *POSTGRADUATE MEDICINE*
Genovese, M. C.

1998; 103 (2): 125-?

- **Dehydroepiandrosterone (DHEA) in severe systemic lupus erythematosus. Results of a double-blinded, placebo controlled pilot study.**
Genovese, M. C., Hendrickson, C. L., Park, J., Powell, M. J., McGuire, J. L., VANVOLLENHOVEN, R. F.
WILEY-BLACKWELL.1997: 168-68
- **Running and osteoarthritis of the knee: A 12 year longitudinal study.**
Lane, N. E., Oehlert, J., Ward, M., Genovese, M., Bloch, D., Fries, J. F.
WILEY-BLACKWELL.1997: 1242-42
- **Fever, rash, and arthritis in a woman with silicone gel breast implants** *WESTERN JOURNAL OF MEDICINE*
Genovese, M. C.
1997; 167 (3): 149-158
- **Lemierre's syndrome** *SOUTHERN MEDICAL JOURNAL*
Lee, B. K., LOPEZ, F., Genovese, M., Loutit, J. S.
1997; 90 (6): 640-643
- **INCIDENCE OF AND RISK-FACTORS FOR HOSPITALIZATIONS IN SYSTEMIC LUPUS-ERYTHEMATOSUS - A PROSPECTIVE-STUDY OF THE HOPKINS LUPUS COHORT** *JOURNAL OF RHEUMATOLOGY*
Petri, M., Genovese, M.
1992; 19 (10): 1559-1559
- **DEFINITION, INCIDENCE, AND CLINICAL DESCRIPTION OF FLARE IN SYSTEMIC LUPUS-ERYTHEMATOSUS - A PROSPECTIVE COHORT STUDY** *ARTHRITIS AND RHEUMATISM*
Petri, M., Genovese, M., Engle, E., Hochberg, M.
1991; 34 (8): 937-944